{
  "paper_id": "PMC10993489",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10993489/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Fig. 1.",
      "caption": "The PRISMA flowchart of literature search and study eligibility strategy",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/41a5087d873e/13643_2024_2520_Fig1_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/41a5087d873e/13643_2024_2520_Fig1_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/41a5087d873e/13643_2024_2520_Fig1_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/41a5087d873e/13643_2024_2520_Fig1_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/41a5087d873e/13643_2024_2520_Fig1_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10993489/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/41a5087d873e/13643_2024_2520_Fig1_HTML.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Fig. 2.",
      "caption": "Pooled pCR outcome of TA-treated Asian breast cancer patients according to molecular subtypes. Forest plots describing the random effect ORs and 95% CIs from studies assessing the association of pCR outcome in NAC TA-treated breast cancer patients between (A) HER2E and luminal-like; (B) HER2E and luminal A; (C) HER2E and luminal B; (D) HER2E and luminal, combined; and (E) TNBC and luminal-like; (F) TNBC and luminal A; (G) TNBC and luminal B; and (H) TNBC and luminal, combined. I2 and p-value for X2 of heterogeneity are reported for each group analysis",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/940772d53e41/13643_2024_2520_Fig2_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/940772d53e41/13643_2024_2520_Fig2_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/940772d53e41/13643_2024_2520_Fig2_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/940772d53e41/13643_2024_2520_Fig2_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/940772d53e41/13643_2024_2520_Fig2_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10993489/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/940772d53e41/13643_2024_2520_Fig2_HTML.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Fig. 3.",
      "caption": "Pooled pCR outcome of TP-treated Asian breast cancer patients according to molecular subtypes. Forest plots describing the random effect ORs and 95% CIs from studies assessing the association of pCR outcome in NAC TP-treated Asian breast cancer patients between (A) HER2E and luminal-like; (B) HER2E and luminal A; (C) HER2E and luminal B; (D) HER2E and luminal, combined; (E) Luminal B and luminal A; (F) TNBC and luminal A; (G) TNBC and luminal B. I2 and p-value for X2 of heterogeneity are reported for each group analysis",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/9dc764e3cecf/13643_2024_2520_Fig3_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/9dc764e3cecf/13643_2024_2520_Fig3_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/9dc764e3cecf/13643_2024_2520_Fig3_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/9dc764e3cecf/13643_2024_2520_Fig3_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig3",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/9dc764e3cecf/13643_2024_2520_Fig3_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10993489/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/9dc764e3cecf/13643_2024_2520_Fig3_HTML.jpg"
    },
    "figure_4": {
      "figure_number": "Figure 4",
      "title": "Fig. 4.",
      "caption": "Pooled pCR outcome of NAC-treated Asian breast cancer patients according to molecular subtypes and biomarkers. Forest plots describing the random effect ORs and 95% CIs from studies assessing the association of pCR outcome in (A) NAC TP-treated Asian breast cancer patients between TNBC and luminal, combined; (B) between Asian TNBC patients treated with NAC TP and TA; Asian breast cancer patients treated with anthracycline-based chemotherapy with (C) ER; (D) PR; and (E) HER2 biomarkers; (F) Asian breast cancer patients treated with taxane-based chemotherapy and HR biomarker; (G) Asian breast cancer patients treated with TA and ER biomarker. I2 and p-value for X2 of heterogeneity are reported for each group analysis",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/613d6f865a03/13643_2024_2520_Fig4_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/613d6f865a03/13643_2024_2520_Fig4_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/613d6f865a03/13643_2024_2520_Fig4_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/613d6f865a03/13643_2024_2520_Fig4_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig4",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/613d6f865a03/13643_2024_2520_Fig4_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10993489/images/figure_4.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/613d6f865a03/13643_2024_2520_Fig4_HTML.jpg"
    },
    "figure_5": {
      "figure_number": "Figure 5",
      "title": "Fig. 5.",
      "caption": "Pooled pCR outcome of TA-treated Asian breast cancer patients according to biomarkers. Forest plots describing the random effect ORs and 95% CIs from studies assessing the association of pCR outcome in NAC TA-treated breast cancer patients in biomarkers (A) PR; (B) HR; (C) HER2; (D) nm23-H1; and (E) CK5/6. I2 and p-value for X2 of heterogeneity are reported for each group analysis",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/a8c216796c6b/13643_2024_2520_Fig5_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/a8c216796c6b/13643_2024_2520_Fig5_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/a8c216796c6b/13643_2024_2520_Fig5_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/a8c216796c6b/13643_2024_2520_Fig5_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig5",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/a8c216796c6b/13643_2024_2520_Fig5_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10993489/images/figure_5.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/a8c216796c6b/13643_2024_2520_Fig5_HTML.jpg"
    },
    "figure_6": {
      "figure_number": "Figure 6",
      "title": "Fig. 6.",
      "caption": "Pooled pCR outcome of NAC-treated Asian breast cancer patients according to biomarkers. Forest plots describing the random effect ORs and 95% CIs from studies assessing the association of pCR outcome in (A) NAC TA-treated breast cancer patients in biomarkers Ki-67; NAC TP-treated breast cancer patients in biomarkers (B) ER; (C) PR; (D) HR; and (E) Ki-67. I2 and p-value for X2 of heterogeneity are reported for each group analysis",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/eb9ebf6947df/13643_2024_2520_Fig6_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/eb9ebf6947df/13643_2024_2520_Fig6_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/eb9ebf6947df/13643_2024_2520_Fig6_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/eb9ebf6947df/13643_2024_2520_Fig6_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig6",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/eb9ebf6947df/13643_2024_2520_Fig6_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10993489/images/figure_6.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/eb9ebf6947df/13643_2024_2520_Fig6_HTML.jpg"
    },
    "figure_7": {
      "figure_number": "Figure 7",
      "title": "Fig. 7.",
      "caption": "Pooled pCR outcome of NAC-treated Asian patients according to biomarkers and genetic variation. Forest plots describing the random effect ORs and 95% CIs from studies assessing the (A) Association of pCR outcome in NAC TP-treated Asian breast cancer patients in HER2; (B) Association between pCR in Asian patients with HER2+ biomarker treated with NAC TP and TA; and (C) Association of pCR outcome in NAC TA-treated Asian breast cancer patients in PIK3CA gene. I2 and p-value for X2 of heterogeneity are reported for each group analysis",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/8c553d75d871/13643_2024_2520_Fig7_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/8c553d75d871/13643_2024_2520_Fig7_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/8c553d75d871/13643_2024_2520_Fig7_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/8c553d75d871/13643_2024_2520_Fig7_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig7",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/8c553d75d871/13643_2024_2520_Fig7_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10993489/images/figure_7.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a68/10993489/8c553d75d871/13643_2024_2520_Fig7_HTML.jpg"
    }
  },
  "claims": [
    {
      "sentence": "Fig. 1 shows how the studies were searched and identified in the various databases and registers.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Finally, 101 studies fulfilled the eligibility criteria and were included in the systematic review and meta-analysis (Fig. 1).Overview of included studies\nAltogether, 19,708 Asian breast cancer patients were gathered from the 101 studies, with an average of 195 patients per study (Supplementary Table 4.1 in Additional file 4).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, the role of molecular subtypes was examined in NAC TA-treated (Figure 2 and Supplementary Figure 7.1 in Additional file 7) and TP-treated (Figures 3 and 4 and Supplementary Figure 7.1 in Additional file 7) breast cancer patients.Taxane-anthracycline (TA) chemotherapy\nOur study first compares the effect of HER2E and luminal subtypes on pCR outcomes in TA-treated patients (Fig. 2A–D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Despite the large number of patients with luminal-like subtypes, our findings significantly associate patients with HER2E subtypes with better pCR outcomes (OR: 4.08; 95% CI; 2.78–6.00; p<0.0001; Fig. 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "When HER2E patients were compared with patients with luminal A subtype, patients with HER2E subtypes were also found to be significantly more likely to achieve pCR (OR 5.27; 95% CI 1.16–23.86; p=0.03; Fig. 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Similarly, when HER2E was analysed against luminal B, HER2E was significantly associated with pCR (OR 2.78; 95% CI 1.42–5.44; p=0.003; Fig. 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Nine studies [34, 35, 71, 80, 84, 95, 98, 100, 113] were pooled, yet our findings still showed that HER2E subtype was significantly associated with pCR outcome in NAC TA-treated patients (OR 3.89; 95% CI 2.69-5.64; p<0.0001; Fig. 2D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Similarly, analyses conducted comparing the effect of TNBC and luminal subtypes on pCR outcome in TA-treated patients (Fig. 2E–H) significantly associate TNBC with better pCR outcome compared to luminal-like (OR 4.45; 95% CI 2.79–7.11; p<0.0001; Fig. 2E), luminal A (OR 11.66; 95% CI 3.64-37.38; p<0.0001; Fig. 2F), luminal B (OR 3.89; 95% CI 2.20–6.87; p<0.0001; Fig. 2G), and luminal, combined (OR 4.59; 95% CI 3.35–6.29; p<0.0001; Fig. 2H).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel E",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel E",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel F",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "To further explore the effect of molecular subtypes on the pCR outcome of NAC TA-treated breast cancer patients, the TNBC subtype was compared to the HER2E subtype revealing that neither was associated with pCR (OR 1.17; 95% CI 0.80-1.70; p=0.43; Supplementary Figure 7.1A in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, an analysis between luminal A and luminal B showed that neither was associated with better pCR outcome when treated with NAC TA (OR 2.47; 95% CI 0.79–7.73; p=0.12; Supplementary Figure 7.1B in Additional file 7).Taxane-platinum (TP) chemotherapy\nIn the analysis pooling three studies [45,64,102] comparing HER2E and luminal-like subtypes, 321 patients were identified with HER2E subtype, and 382 patients were luminal-like.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "When treated with NAC TP, neither HER2E nor luminal-like patients were associated with pCR (OR 1.69; 95% CI 0.70–4.11; p=0.25; Fig. 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "However, in the analysis pooling four studies [41, 69, 97, 115] comparing HER2E and luminal A subtypes, HER2E was significantly associated with pCR outcome (OR 12.11; 95% CI 4.41–33.26; p<0.0001; Fig. 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Similarly, when comparing against luminal B and luminal, combined, HER2E was significantly associated with pCR outcome (OR 5.92; 95% CI 2.59–13.54; p<0.0001; Fig. 3C and OR 3.37; 95% CI 1.66–6.84; p=0.0008; Fig. 3D, respectively).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Substantial heterogeneity was reported for two of the pooled analyses: (1) in studies comparing HER2E and luminal-like (Fig. 3A); and (2) in studies comparing HER2E and luminal, combined (Fig. 3D).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Notably, when HER2E and TNBC patients were compared, neither was associated with pCR (OR 1.46; 95% CI 0.63–3.37; p=0.38; Supplementary Figure 7.1C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "We then compared luminal B and luminal A patients and found that luminal B patients were significantly associated with better pCR outcomes (OR 3.26; 95% CI 1.14–9.26; p=0.03; Fig. 3E).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Similar to NAC TA-treated patients, analyses conducted comparing the effect of TNBC and luminal subtypes on pCR outcome in TP-treated patients also significantly associate TNBC with better pCR outcome compared to luminal A (OR 7.14; 95% CI 2.82–18.04; p<0.0001; Fig. 3F), luminal B (OR 2.19; 95% CI 1.09–4.41; p=0.03; Fig. 3G), and luminal, combined (OR 3.79; 95% CI 1.94–7.40; p<0.0001; Fig. 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Our study compared the effect of chemotherapeutic agents on the pCR outcome in TNBC patients (Fig. 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, the role of biomarkers was investigated in NAC anthracycline-based and taxane-based treated (Fig. 4), TA-treated (Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "4, 5 and 6 and Supplementary Figure 7.1 in Additional file 7), and TP-treated (Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "6 and 7) breast cancer patients.Anthracycline-based and taxane-based chemotherapy\nFour studies [53, 88, 102, 124] were pooled for the effect of ER on pCR outcome in anthracycline-treated patients, where ER was not associated with pCR (OR 1.95; 95% CI 0.98–3.89; p=0.06; Fig. 4C).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Subgroup analysis of ER− vs ER+ pooling studies in the Chinese population only showed that ER− patients were significantly associated with pCR (OR 2.52; 95% CI 1.43–4.44; p=0.001; Fig. 4C), supporting our hypothesis that the observed heterogeneity could be due to the difference in the Asian population.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Our findings showed that PR− patients were significantly associated with pCR (OR 2.40; 95% CI 1.52–3.80; p=0.0002; Fig. 4D).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel D",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Meanwhile, an analysis of three pooled studies [88, 102, 109] on the effect of HER2 on pCR outcome in anthracycline-treated breast cancer patients revealed that patients with HER2− biomarker were significantly more likely to achieve pCR (OR 2.31; 95% CI 1.42–3.75; p=0.0008; Fig. 4E).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel E",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Only one biomarker, HR, was evaluated for its effect on pCR outcome in Asian breast cancer patients treated with taxane-based chemotherapy (Fig. 4F).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Both ER− (OR 3.19; 95% CI 2.15–4.75; p<0.0001; Fig. 4G) and PR− (OR 3.11; 95% CI 2.12-4.56; p<0.0001; Fig. 5A) were significantly associated with pCR outcome in TA-treated patients.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel G",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "In an analysis pooling five studies [60, 81, 98, 100, 127], HR was not associated with pCR outcome (OR 2.38; 95% CI 0.87–6.53; p=0.09; Fig. 5B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "An analysis of nine pooled studies [36, 54, 60, 80–82, 100, 113, 127] showed that HER2+ is significantly associated with pCR (OR 1.78; 95% CI 1.05–3.02; p=0.03; Fig. 5C) with substantial heterogeneity observed between the studies.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "It was observed that nm23-H1− (OR 6.74; 95% CI 2.13–21.30; p=0.001; Fig. 5D) and CK5/6– (OR 1.87; 95% CI 1.03–3.39; p=0.04; Fig. 5E) are significantly associated with pCR.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel D",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel E",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Despite that, EGFR is not associated with pCR outcome in TA-treated patients (OR 2.02; 95% CI 0.28–28.00; p=0.38; Supplementary Figure 7.1D in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The proliferation index biomarker, Ki-67, was evaluated through an analysis of 12 pooled studies [12, 36, 54, 60, 80, 84, 90, 95, 98, 100, 111, 127], revealing significant association between pCR outcome and high Ki-67 (OR 2.98; 95% CI 1.79–4.97; p<0.0001; Fig. 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Five studies [41, 43, 97, 114, 115] and two studies [100,102] were pooled to evaluate the association of ER and PR, and HR, respectively. pCR outcome was significantly associated with ER− (OR 4.91; 95% CI 3.20–7.53; p<0.00001; Fig. 6B), PR− (OR 3.82; 95% CI 2.48–5.90; p<0.00001; Fig. 6C), and HR− (OR 2.71; 95% CI 1.43–5.15; p=0.002; Fig. 6D).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel D",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Ki-67 was evaluated by analysing five pooled studies [47, 57, 97, 114, 115], showing that pCR outcome was not significantly associated with either high Ki-67 or low Ki-67 (OR 2.20; 95% CI 0.74–6.59; p=0.16; Fig. 6E).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel E",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "In the analysis of the effect of HER2 in breast cancer patients pooling five studies [41, 43, 97, 114, 115], pCR outcome was not significantly associated with neither HER2+ nor HER2− (OR 2.44; 95% CI 0.84–7.06; p=0.10; Fig. 7A).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel A",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Our study also evaluated the effect of chemotherapeutic agents on the pCR outcome in Asian breast cancer patients with HER2+ biomarker (Fig. 7B).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, only one gene was analysed for its effect on pCR outcome in Asian breast cancer patients treated with NAC TA (Fig. 7).Taxane-anthracycline (TA) chemotherapy\nFrom the analysis of two studies [100, 106], 564 patients were pooled for PIK3CA analysis.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "It was observed that patients harbouring wtPIK3CA were significantly associated with better pCRoutcomes compared to patients with mtPIK3CA gene (OR: 2.44; 95% CI 1.42–4.19; p=0.001; Fig. 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Process\n\nSearch (n=5746)\nExcluded with reasons [refer to Figure 1 for detailed reasons] (n=5610)\nExcluded after reviewing full-text (n=35)\nIncluded studies (n=101)\n\n\n\nResults\n\nWhere statistically appropriate, studies were pooled.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Open in a new tabPooled reported association\nMeta-analyses of pooled reported association of pCR were evaluated according to molecular classification, genetic variations, and biomarkers characterisation of the Asian breast cancer patients.Molecular classification\nAn adjusted pooled analysis of TNBC against non-TNBC patients showed that TNBC patients were significantly associated with better response when treated with neoadjuvant chemotherapy (OR 3.02; 95% CI 1.54–5.95; p=0.001; Supplementary Figure 7.2A in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "In the adjusted analysis of three [51, 100, 106] and two studies [51, 100] for PIK3CA and TP53 genes, respectively, breast cancer patients harbouring mutation in the PIK3CA gene was associated with worse response (OR 0.64; 95% CI 0.42-0.98; p=0.04; Supplementary Figure 7.2B in Additional file 7) while TP53 gene was not associated with pCR outcome (OR 1.34; 95% CI 0.59–3.05; p=0.49; Supplementary Figure 7.2B in Additional file 7).Biomarkers\nAmongst pooled reported associations of pCR for biomarkers, our study evaluated the effect of Tau, nm23-H1, ER, PR, HR, HER2, and Ki-67 biomarkers in NAC-treated Asian BC patients (Supplementary Figures 7.2–7.8 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "In an adjusted analysis of Tau pooling two studies [61, 83], the result suggests that Tau+ was associated with worse response in the neoadjuvant setting (OR 0.22, 95% CI 0.09–0.54, p=0.0008; Supplementary Figure 7.2C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile in adjusted analysis of nm23-H1 pooling two studies [12, 60], nm23-H1 was not associated with pCR outcome in TA-treated patients (OR 1.56, 95% CI 0.55–4.45, p=0.41; Supplementary Figure 7.2C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between pCR in NAC-treated breast cancer patients and ER was evaluated in Supplementary Figure 7.3 (Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile, adjusted analysis of ER+ vs ER− pooling fourteen studies [54, 56, 61, 68, 71, 72, 83, 94, 97, 102, 103, 106, 112, 131] also showed that ER was not associated with pCR outcome (OR 0.59; 95% CI 0.32–1.08; p=0.09; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile, analyses pooling studies based on the characteristics of the patients showed that ER was not associated with pCR in patients achieving a complete pathological response in the breast only (OR 0.93; 95% CI 0.18–4.85; p=0.94; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Notably, ER− patients were significantly associated with pCR in studies pooling anthracycline-treated patients (OR 2.78; 95% CI 1.61–4.78; p=0.0002; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The role of the biomarker PR was assessed in Asian breast cancer patients subjected to neoadjuvant chemotherapy (Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "PR was also not associated with treatment response in the adjusted analysis pooling eight studies [54, 56, 61, 94, 97, 102, 103, 106] (OR 1.01; 95% CI 0.64–1.60; p=0.97; Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between treatment response and hormone receptors (HR) comprising ER and PR was assessed in Asian breast cancer patients (Supplementary Figure 7.5 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, analysis with adjusted OR pooling five studies [51, 60, 62, 64, 70] indicated that HR was not significantly associated with treatment response (OR 1.27; 95% CI 0.47–3.45; p=0.64; Supplementary Figure 7.5 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between pCR outcome and HER2 was estimated in Supplementary Figure 7.6 (Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, in an analysis pooling adjusted OR of 12 studies [56, 60, 61, 70, 77, 83, 94, 97, 102, 103, 106, 131], it was observed that HER2+ breast cancer patients were significantly associated with better treatment response (OR 2.29; 95% CI 1.56–3.35; p<0.0001; Supplementary Figure 7.6 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Notably, HER2 was also not associated with pCR in patients achieving a complete pathological response in the breast only (OR 1.96; 95% CI 0.78–4.89; p=0.15; Supplementary Figure 7.6 in Additional file 7) and in anthracycline-treated patients (OR 1.52; 95% CI 0.97–2.40; p=0.07; Supplementary Figure 7.6 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As for Ki-67, an analysis pooling crude OR of eight studies [46, 51, 61, 64, 94, 97, 115, 123] observed that patients with high Ki-67 were significantly associated with better treatment responses (OR 2.63; 95% CI 1.69–4.07; p<0.0001; Supplementary Figure 7.7 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, an analysis of adjusted OR pooling seven studies [12, 46, 51, 54, 94, 97, 110] showed that patients with high Ki-67 were significantly associated with better treatment response (OR 2.63; 95% CI 1.56–4.41; p=0.0003; Supplementary Figure 7.7 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Three biomarkers—ER, HR, and Ki-67—were evaluated by pooling studies reporting their association using hazards ratio (Supplementary Figure 7.8 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As indicated in Fig. 5, subgroup analysis was not conducted for the overall analysis because although the effect is estimated to favour HER2+ significantly, in some studies the true effect may in fact favour HER2−.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Thus, four subsequent subgroup analyses—pooling two studies at each treatment regimen the patients were subjected to—were conducted for the overall PR− vs PR+ (adjusted results) analysis (Supplementary Figure 7.4 in Additional file 7).Discussion\nThere are many options for breast cancer treatment.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Fig. 1 shows how the studies were searched and identified in the various databases and registers.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Finally, 101 studies fulfilled the eligibility criteria and were included in the systematic review and meta-analysis (Fig. 1).Overview of included studies\nAltogether, 19,708 Asian breast cancer patients were gathered from the 101 studies, with an average of 195 patients per study (Supplementary Table 4.1 in Additional file 4).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, the role of molecular subtypes was examined in NAC TA-treated (Figure 2 and Supplementary Figure 7.1 in Additional file 7) and TP-treated (Figures 3 and 4 and Supplementary Figure 7.1 in Additional file 7) breast cancer patients.Taxane-anthracycline (TA) chemotherapy\nOur study first compares the effect of HER2E and luminal subtypes on pCR outcomes in TA-treated patients (Fig. 2A–D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Despite the large number of patients with luminal-like subtypes, our findings significantly associate patients with HER2E subtypes with better pCR outcomes (OR: 4.08; 95% CI; 2.78–6.00; p<0.0001; Fig. 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "When HER2E patients were compared with patients with luminal A subtype, patients with HER2E subtypes were also found to be significantly more likely to achieve pCR (OR 5.27; 95% CI 1.16–23.86; p=0.03; Fig. 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Similarly, when HER2E was analysed against luminal B, HER2E was significantly associated with pCR (OR 2.78; 95% CI 1.42–5.44; p=0.003; Fig. 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Nine studies [34, 35, 71, 80, 84, 95, 98, 100, 113] were pooled, yet our findings still showed that HER2E subtype was significantly associated with pCR outcome in NAC TA-treated patients (OR 3.89; 95% CI 2.69-5.64; p<0.0001; Fig. 2D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Similarly, analyses conducted comparing the effect of TNBC and luminal subtypes on pCR outcome in TA-treated patients (Fig. 2E–H) significantly associate TNBC with better pCR outcome compared to luminal-like (OR 4.45; 95% CI 2.79–7.11; p<0.0001; Fig. 2E), luminal A (OR 11.66; 95% CI 3.64-37.38; p<0.0001; Fig. 2F), luminal B (OR 3.89; 95% CI 2.20–6.87; p<0.0001; Fig. 2G), and luminal, combined (OR 4.59; 95% CI 3.35–6.29; p<0.0001; Fig. 2H).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel E",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel E",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel F",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "To further explore the effect of molecular subtypes on the pCR outcome of NAC TA-treated breast cancer patients, the TNBC subtype was compared to the HER2E subtype revealing that neither was associated with pCR (OR 1.17; 95% CI 0.80-1.70; p=0.43; Supplementary Figure 7.1A in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, an analysis between luminal A and luminal B showed that neither was associated with better pCR outcome when treated with NAC TA (OR 2.47; 95% CI 0.79–7.73; p=0.12; Supplementary Figure 7.1B in Additional file 7).Taxane-platinum (TP) chemotherapy\nIn the analysis pooling three studies [45,64,102] comparing HER2E and luminal-like subtypes, 321 patients were identified with HER2E subtype, and 382 patients were luminal-like.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "When treated with NAC TP, neither HER2E nor luminal-like patients were associated with pCR (OR 1.69; 95% CI 0.70–4.11; p=0.25; Fig. 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "However, in the analysis pooling four studies [41, 69, 97, 115] comparing HER2E and luminal A subtypes, HER2E was significantly associated with pCR outcome (OR 12.11; 95% CI 4.41–33.26; p<0.0001; Fig. 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Similarly, when comparing against luminal B and luminal, combined, HER2E was significantly associated with pCR outcome (OR 5.92; 95% CI 2.59–13.54; p<0.0001; Fig. 3C and OR 3.37; 95% CI 1.66–6.84; p=0.0008; Fig. 3D, respectively).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Substantial heterogeneity was reported for two of the pooled analyses: (1) in studies comparing HER2E and luminal-like (Fig. 3A); and (2) in studies comparing HER2E and luminal, combined (Fig. 3D).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Notably, when HER2E and TNBC patients were compared, neither was associated with pCR (OR 1.46; 95% CI 0.63–3.37; p=0.38; Supplementary Figure 7.1C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "We then compared luminal B and luminal A patients and found that luminal B patients were significantly associated with better pCR outcomes (OR 3.26; 95% CI 1.14–9.26; p=0.03; Fig. 3E).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Similar to NAC TA-treated patients, analyses conducted comparing the effect of TNBC and luminal subtypes on pCR outcome in TP-treated patients also significantly associate TNBC with better pCR outcome compared to luminal A (OR 7.14; 95% CI 2.82–18.04; p<0.0001; Fig. 3F), luminal B (OR 2.19; 95% CI 1.09–4.41; p=0.03; Fig. 3G), and luminal, combined (OR 3.79; 95% CI 1.94–7.40; p<0.0001; Fig. 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Our study compared the effect of chemotherapeutic agents on the pCR outcome in TNBC patients (Fig. 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, the role of biomarkers was investigated in NAC anthracycline-based and taxane-based treated (Fig. 4), TA-treated (Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "4, 5 and 6 and Supplementary Figure 7.1 in Additional file 7), and TP-treated (Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "6 and 7) breast cancer patients.Anthracycline-based and taxane-based chemotherapy\nFour studies [53, 88, 102, 124] were pooled for the effect of ER on pCR outcome in anthracycline-treated patients, where ER was not associated with pCR (OR 1.95; 95% CI 0.98–3.89; p=0.06; Fig. 4C).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Subgroup analysis of ER− vs ER+ pooling studies in the Chinese population only showed that ER− patients were significantly associated with pCR (OR 2.52; 95% CI 1.43–4.44; p=0.001; Fig. 4C), supporting our hypothesis that the observed heterogeneity could be due to the difference in the Asian population.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Our findings showed that PR− patients were significantly associated with pCR (OR 2.40; 95% CI 1.52–3.80; p=0.0002; Fig. 4D).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel D",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Meanwhile, an analysis of three pooled studies [88, 102, 109] on the effect of HER2 on pCR outcome in anthracycline-treated breast cancer patients revealed that patients with HER2− biomarker were significantly more likely to achieve pCR (OR 2.31; 95% CI 1.42–3.75; p=0.0008; Fig. 4E).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel E",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Only one biomarker, HR, was evaluated for its effect on pCR outcome in Asian breast cancer patients treated with taxane-based chemotherapy (Fig. 4F).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Both ER− (OR 3.19; 95% CI 2.15–4.75; p<0.0001; Fig. 4G) and PR− (OR 3.11; 95% CI 2.12-4.56; p<0.0001; Fig. 5A) were significantly associated with pCR outcome in TA-treated patients.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel G",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "In an analysis pooling five studies [60, 81, 98, 100, 127], HR was not associated with pCR outcome (OR 2.38; 95% CI 0.87–6.53; p=0.09; Fig. 5B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "An analysis of nine pooled studies [36, 54, 60, 80–82, 100, 113, 127] showed that HER2+ is significantly associated with pCR (OR 1.78; 95% CI 1.05–3.02; p=0.03; Fig. 5C) with substantial heterogeneity observed between the studies.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "It was observed that nm23-H1− (OR 6.74; 95% CI 2.13–21.30; p=0.001; Fig. 5D) and CK5/6– (OR 1.87; 95% CI 1.03–3.39; p=0.04; Fig. 5E) are significantly associated with pCR.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel D",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel E",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Despite that, EGFR is not associated with pCR outcome in TA-treated patients (OR 2.02; 95% CI 0.28–28.00; p=0.38; Supplementary Figure 7.1D in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The proliferation index biomarker, Ki-67, was evaluated through an analysis of 12 pooled studies [12, 36, 54, 60, 80, 84, 90, 95, 98, 100, 111, 127], revealing significant association between pCR outcome and high Ki-67 (OR 2.98; 95% CI 1.79–4.97; p<0.0001; Fig. 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Five studies [41, 43, 97, 114, 115] and two studies [100,102] were pooled to evaluate the association of ER and PR, and HR, respectively. pCR outcome was significantly associated with ER− (OR 4.91; 95% CI 3.20–7.53; p<0.00001; Fig. 6B), PR− (OR 3.82; 95% CI 2.48–5.90; p<0.00001; Fig. 6C), and HR− (OR 2.71; 95% CI 1.43–5.15; p=0.002; Fig. 6D).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel D",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Ki-67 was evaluated by analysing five pooled studies [47, 57, 97, 114, 115], showing that pCR outcome was not significantly associated with either high Ki-67 or low Ki-67 (OR 2.20; 95% CI 0.74–6.59; p=0.16; Fig. 6E).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel E",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "In the analysis of the effect of HER2 in breast cancer patients pooling five studies [41, 43, 97, 114, 115], pCR outcome was not significantly associated with neither HER2+ nor HER2− (OR 2.44; 95% CI 0.84–7.06; p=0.10; Fig. 7A).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel A",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Our study also evaluated the effect of chemotherapeutic agents on the pCR outcome in Asian breast cancer patients with HER2+ biomarker (Fig. 7B).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, only one gene was analysed for its effect on pCR outcome in Asian breast cancer patients treated with NAC TA (Fig. 7).Taxane-anthracycline (TA) chemotherapy\nFrom the analysis of two studies [100, 106], 564 patients were pooled for PIK3CA analysis.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "It was observed that patients harbouring wtPIK3CA were significantly associated with better pCRoutcomes compared to patients with mtPIK3CA gene (OR: 2.44; 95% CI 1.42–4.19; p=0.001; Fig. 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Process\n\nSearch (n=5746)\nExcluded with reasons [refer to Figure 1 for detailed reasons] (n=5610)\nExcluded after reviewing full-text (n=35)\nIncluded studies (n=101)\n\n\n\nResults\n\nWhere statistically appropriate, studies were pooled.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Open in a new tabPooled reported association\nMeta-analyses of pooled reported association of pCR were evaluated according to molecular classification, genetic variations, and biomarkers characterisation of the Asian breast cancer patients.Molecular classification\nAn adjusted pooled analysis of TNBC against non-TNBC patients showed that TNBC patients were significantly associated with better response when treated with neoadjuvant chemotherapy (OR 3.02; 95% CI 1.54–5.95; p=0.001; Supplementary Figure 7.2A in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "In the adjusted analysis of three [51, 100, 106] and two studies [51, 100] for PIK3CA and TP53 genes, respectively, breast cancer patients harbouring mutation in the PIK3CA gene was associated with worse response (OR 0.64; 95% CI 0.42-0.98; p=0.04; Supplementary Figure 7.2B in Additional file 7) while TP53 gene was not associated with pCR outcome (OR 1.34; 95% CI 0.59–3.05; p=0.49; Supplementary Figure 7.2B in Additional file 7).Biomarkers\nAmongst pooled reported associations of pCR for biomarkers, our study evaluated the effect of Tau, nm23-H1, ER, PR, HR, HER2, and Ki-67 biomarkers in NAC-treated Asian BC patients (Supplementary Figures 7.2–7.8 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "In an adjusted analysis of Tau pooling two studies [61, 83], the result suggests that Tau+ was associated with worse response in the neoadjuvant setting (OR 0.22, 95% CI 0.09–0.54, p=0.0008; Supplementary Figure 7.2C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile in adjusted analysis of nm23-H1 pooling two studies [12, 60], nm23-H1 was not associated with pCR outcome in TA-treated patients (OR 1.56, 95% CI 0.55–4.45, p=0.41; Supplementary Figure 7.2C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between pCR in NAC-treated breast cancer patients and ER was evaluated in Supplementary Figure 7.3 (Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile, adjusted analysis of ER+ vs ER− pooling fourteen studies [54, 56, 61, 68, 71, 72, 83, 94, 97, 102, 103, 106, 112, 131] also showed that ER was not associated with pCR outcome (OR 0.59; 95% CI 0.32–1.08; p=0.09; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile, analyses pooling studies based on the characteristics of the patients showed that ER was not associated with pCR in patients achieving a complete pathological response in the breast only (OR 0.93; 95% CI 0.18–4.85; p=0.94; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Notably, ER− patients were significantly associated with pCR in studies pooling anthracycline-treated patients (OR 2.78; 95% CI 1.61–4.78; p=0.0002; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The role of the biomarker PR was assessed in Asian breast cancer patients subjected to neoadjuvant chemotherapy (Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "PR was also not associated with treatment response in the adjusted analysis pooling eight studies [54, 56, 61, 94, 97, 102, 103, 106] (OR 1.01; 95% CI 0.64–1.60; p=0.97; Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between treatment response and hormone receptors (HR) comprising ER and PR was assessed in Asian breast cancer patients (Supplementary Figure 7.5 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, analysis with adjusted OR pooling five studies [51, 60, 62, 64, 70] indicated that HR was not significantly associated with treatment response (OR 1.27; 95% CI 0.47–3.45; p=0.64; Supplementary Figure 7.5 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between pCR outcome and HER2 was estimated in Supplementary Figure 7.6 (Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, in an analysis pooling adjusted OR of 12 studies [56, 60, 61, 70, 77, 83, 94, 97, 102, 103, 106, 131], it was observed that HER2+ breast cancer patients were significantly associated with better treatment response (OR 2.29; 95% CI 1.56–3.35; p<0.0001; Supplementary Figure 7.6 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Notably, HER2 was also not associated with pCR in patients achieving a complete pathological response in the breast only (OR 1.96; 95% CI 0.78–4.89; p=0.15; Supplementary Figure 7.6 in Additional file 7) and in anthracycline-treated patients (OR 1.52; 95% CI 0.97–2.40; p=0.07; Supplementary Figure 7.6 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As for Ki-67, an analysis pooling crude OR of eight studies [46, 51, 61, 64, 94, 97, 115, 123] observed that patients with high Ki-67 were significantly associated with better treatment responses (OR 2.63; 95% CI 1.69–4.07; p<0.0001; Supplementary Figure 7.7 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, an analysis of adjusted OR pooling seven studies [12, 46, 51, 54, 94, 97, 110] showed that patients with high Ki-67 were significantly associated with better treatment response (OR 2.63; 95% CI 1.56–4.41; p=0.0003; Supplementary Figure 7.7 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Three biomarkers—ER, HR, and Ki-67—were evaluated by pooling studies reporting their association using hazards ratio (Supplementary Figure 7.8 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As indicated in Fig. 5, subgroup analysis was not conducted for the overall analysis because although the effect is estimated to favour HER2+ significantly, in some studies the true effect may in fact favour HER2−.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Thus, four subsequent subgroup analyses—pooling two studies at each treatment regimen the patients were subjected to—were conducted for the overall PR− vs PR+ (adjusted results) analysis (Supplementary Figure 7.4 in Additional file 7).Discussion\nThere are many options for breast cancer treatment.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Fig. 1 shows how the studies were searched and identified in the various databases and registers.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Finally, 101 studies fulfilled the eligibility criteria and were included in the systematic review and meta-analysis (Fig. 1).Overview of included studies\nAltogether, 19,708 Asian breast cancer patients were gathered from the 101 studies, with an average of 195 patients per study (Supplementary Table 4.1 in Additional file 4).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, the role of molecular subtypes was examined in NAC TA-treated (Figure 2 and Supplementary Figure 7.1 in Additional file 7) and TP-treated (Figures 3 and 4 and Supplementary Figure 7.1 in Additional file 7) breast cancer patients.Taxane-anthracycline (TA) chemotherapy\nOur study first compares the effect of HER2E and luminal subtypes on pCR outcomes in TA-treated patients (Fig. 2A–D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Despite the large number of patients with luminal-like subtypes, our findings significantly associate patients with HER2E subtypes with better pCR outcomes (OR: 4.08; 95% CI; 2.78–6.00; p<0.0001; Fig. 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "When HER2E patients were compared with patients with luminal A subtype, patients with HER2E subtypes were also found to be significantly more likely to achieve pCR (OR 5.27; 95% CI 1.16–23.86; p=0.03; Fig. 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Similarly, when HER2E was analysed against luminal B, HER2E was significantly associated with pCR (OR 2.78; 95% CI 1.42–5.44; p=0.003; Fig. 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Nine studies [34, 35, 71, 80, 84, 95, 98, 100, 113] were pooled, yet our findings still showed that HER2E subtype was significantly associated with pCR outcome in NAC TA-treated patients (OR 3.89; 95% CI 2.69-5.64; p<0.0001; Fig. 2D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Similarly, analyses conducted comparing the effect of TNBC and luminal subtypes on pCR outcome in TA-treated patients (Fig. 2E–H) significantly associate TNBC with better pCR outcome compared to luminal-like (OR 4.45; 95% CI 2.79–7.11; p<0.0001; Fig. 2E), luminal A (OR 11.66; 95% CI 3.64-37.38; p<0.0001; Fig. 2F), luminal B (OR 3.89; 95% CI 2.20–6.87; p<0.0001; Fig. 2G), and luminal, combined (OR 4.59; 95% CI 3.35–6.29; p<0.0001; Fig. 2H).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel E",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel E",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel F",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "To further explore the effect of molecular subtypes on the pCR outcome of NAC TA-treated breast cancer patients, the TNBC subtype was compared to the HER2E subtype revealing that neither was associated with pCR (OR 1.17; 95% CI 0.80-1.70; p=0.43; Supplementary Figure 7.1A in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, an analysis between luminal A and luminal B showed that neither was associated with better pCR outcome when treated with NAC TA (OR 2.47; 95% CI 0.79–7.73; p=0.12; Supplementary Figure 7.1B in Additional file 7).Taxane-platinum (TP) chemotherapy\nIn the analysis pooling three studies [45,64,102] comparing HER2E and luminal-like subtypes, 321 patients were identified with HER2E subtype, and 382 patients were luminal-like.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "When treated with NAC TP, neither HER2E nor luminal-like patients were associated with pCR (OR 1.69; 95% CI 0.70–4.11; p=0.25; Fig. 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "However, in the analysis pooling four studies [41, 69, 97, 115] comparing HER2E and luminal A subtypes, HER2E was significantly associated with pCR outcome (OR 12.11; 95% CI 4.41–33.26; p<0.0001; Fig. 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Similarly, when comparing against luminal B and luminal, combined, HER2E was significantly associated with pCR outcome (OR 5.92; 95% CI 2.59–13.54; p<0.0001; Fig. 3C and OR 3.37; 95% CI 1.66–6.84; p=0.0008; Fig. 3D, respectively).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Substantial heterogeneity was reported for two of the pooled analyses: (1) in studies comparing HER2E and luminal-like (Fig. 3A); and (2) in studies comparing HER2E and luminal, combined (Fig. 3D).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Notably, when HER2E and TNBC patients were compared, neither was associated with pCR (OR 1.46; 95% CI 0.63–3.37; p=0.38; Supplementary Figure 7.1C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "We then compared luminal B and luminal A patients and found that luminal B patients were significantly associated with better pCR outcomes (OR 3.26; 95% CI 1.14–9.26; p=0.03; Fig. 3E).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Similar to NAC TA-treated patients, analyses conducted comparing the effect of TNBC and luminal subtypes on pCR outcome in TP-treated patients also significantly associate TNBC with better pCR outcome compared to luminal A (OR 7.14; 95% CI 2.82–18.04; p<0.0001; Fig. 3F), luminal B (OR 2.19; 95% CI 1.09–4.41; p=0.03; Fig. 3G), and luminal, combined (OR 3.79; 95% CI 1.94–7.40; p<0.0001; Fig. 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Our study compared the effect of chemotherapeutic agents on the pCR outcome in TNBC patients (Fig. 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, the role of biomarkers was investigated in NAC anthracycline-based and taxane-based treated (Fig. 4), TA-treated (Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "4, 5 and 6 and Supplementary Figure 7.1 in Additional file 7), and TP-treated (Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "6 and 7) breast cancer patients.Anthracycline-based and taxane-based chemotherapy\nFour studies [53, 88, 102, 124] were pooled for the effect of ER on pCR outcome in anthracycline-treated patients, where ER was not associated with pCR (OR 1.95; 95% CI 0.98–3.89; p=0.06; Fig. 4C).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Subgroup analysis of ER− vs ER+ pooling studies in the Chinese population only showed that ER− patients were significantly associated with pCR (OR 2.52; 95% CI 1.43–4.44; p=0.001; Fig. 4C), supporting our hypothesis that the observed heterogeneity could be due to the difference in the Asian population.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Our findings showed that PR− patients were significantly associated with pCR (OR 2.40; 95% CI 1.52–3.80; p=0.0002; Fig. 4D).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel D",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Meanwhile, an analysis of three pooled studies [88, 102, 109] on the effect of HER2 on pCR outcome in anthracycline-treated breast cancer patients revealed that patients with HER2− biomarker were significantly more likely to achieve pCR (OR 2.31; 95% CI 1.42–3.75; p=0.0008; Fig. 4E).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel E",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Only one biomarker, HR, was evaluated for its effect on pCR outcome in Asian breast cancer patients treated with taxane-based chemotherapy (Fig. 4F).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Both ER− (OR 3.19; 95% CI 2.15–4.75; p<0.0001; Fig. 4G) and PR− (OR 3.11; 95% CI 2.12-4.56; p<0.0001; Fig. 5A) were significantly associated with pCR outcome in TA-treated patients.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel G",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "In an analysis pooling five studies [60, 81, 98, 100, 127], HR was not associated with pCR outcome (OR 2.38; 95% CI 0.87–6.53; p=0.09; Fig. 5B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "An analysis of nine pooled studies [36, 54, 60, 80–82, 100, 113, 127] showed that HER2+ is significantly associated with pCR (OR 1.78; 95% CI 1.05–3.02; p=0.03; Fig. 5C) with substantial heterogeneity observed between the studies.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "It was observed that nm23-H1− (OR 6.74; 95% CI 2.13–21.30; p=0.001; Fig. 5D) and CK5/6– (OR 1.87; 95% CI 1.03–3.39; p=0.04; Fig. 5E) are significantly associated with pCR.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel D",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel E",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Despite that, EGFR is not associated with pCR outcome in TA-treated patients (OR 2.02; 95% CI 0.28–28.00; p=0.38; Supplementary Figure 7.1D in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The proliferation index biomarker, Ki-67, was evaluated through an analysis of 12 pooled studies [12, 36, 54, 60, 80, 84, 90, 95, 98, 100, 111, 127], revealing significant association between pCR outcome and high Ki-67 (OR 2.98; 95% CI 1.79–4.97; p<0.0001; Fig. 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Five studies [41, 43, 97, 114, 115] and two studies [100,102] were pooled to evaluate the association of ER and PR, and HR, respectively. pCR outcome was significantly associated with ER− (OR 4.91; 95% CI 3.20–7.53; p<0.00001; Fig. 6B), PR− (OR 3.82; 95% CI 2.48–5.90; p<0.00001; Fig. 6C), and HR− (OR 2.71; 95% CI 1.43–5.15; p=0.002; Fig. 6D).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel D",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Ki-67 was evaluated by analysing five pooled studies [47, 57, 97, 114, 115], showing that pCR outcome was not significantly associated with either high Ki-67 or low Ki-67 (OR 2.20; 95% CI 0.74–6.59; p=0.16; Fig. 6E).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel E",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "In the analysis of the effect of HER2 in breast cancer patients pooling five studies [41, 43, 97, 114, 115], pCR outcome was not significantly associated with neither HER2+ nor HER2− (OR 2.44; 95% CI 0.84–7.06; p=0.10; Fig. 7A).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel A",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Our study also evaluated the effect of chemotherapeutic agents on the pCR outcome in Asian breast cancer patients with HER2+ biomarker (Fig. 7B).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, only one gene was analysed for its effect on pCR outcome in Asian breast cancer patients treated with NAC TA (Fig. 7).Taxane-anthracycline (TA) chemotherapy\nFrom the analysis of two studies [100, 106], 564 patients were pooled for PIK3CA analysis.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "It was observed that patients harbouring wtPIK3CA were significantly associated with better pCRoutcomes compared to patients with mtPIK3CA gene (OR: 2.44; 95% CI 1.42–4.19; p=0.001; Fig. 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Process\n\nSearch (n=5746)\nExcluded with reasons [refer to Figure 1 for detailed reasons] (n=5610)\nExcluded after reviewing full-text (n=35)\nIncluded studies (n=101)\n\n\n\nResults\n\nWhere statistically appropriate, studies were pooled.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Open in a new tabPooled reported association\nMeta-analyses of pooled reported association of pCR were evaluated according to molecular classification, genetic variations, and biomarkers characterisation of the Asian breast cancer patients.Molecular classification\nAn adjusted pooled analysis of TNBC against non-TNBC patients showed that TNBC patients were significantly associated with better response when treated with neoadjuvant chemotherapy (OR 3.02; 95% CI 1.54–5.95; p=0.001; Supplementary Figure 7.2A in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "In the adjusted analysis of three [51, 100, 106] and two studies [51, 100] for PIK3CA and TP53 genes, respectively, breast cancer patients harbouring mutation in the PIK3CA gene was associated with worse response (OR 0.64; 95% CI 0.42-0.98; p=0.04; Supplementary Figure 7.2B in Additional file 7) while TP53 gene was not associated with pCR outcome (OR 1.34; 95% CI 0.59–3.05; p=0.49; Supplementary Figure 7.2B in Additional file 7).Biomarkers\nAmongst pooled reported associations of pCR for biomarkers, our study evaluated the effect of Tau, nm23-H1, ER, PR, HR, HER2, and Ki-67 biomarkers in NAC-treated Asian BC patients (Supplementary Figures 7.2–7.8 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "In an adjusted analysis of Tau pooling two studies [61, 83], the result suggests that Tau+ was associated with worse response in the neoadjuvant setting (OR 0.22, 95% CI 0.09–0.54, p=0.0008; Supplementary Figure 7.2C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile in adjusted analysis of nm23-H1 pooling two studies [12, 60], nm23-H1 was not associated with pCR outcome in TA-treated patients (OR 1.56, 95% CI 0.55–4.45, p=0.41; Supplementary Figure 7.2C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between pCR in NAC-treated breast cancer patients and ER was evaluated in Supplementary Figure 7.3 (Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile, adjusted analysis of ER+ vs ER− pooling fourteen studies [54, 56, 61, 68, 71, 72, 83, 94, 97, 102, 103, 106, 112, 131] also showed that ER was not associated with pCR outcome (OR 0.59; 95% CI 0.32–1.08; p=0.09; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile, analyses pooling studies based on the characteristics of the patients showed that ER was not associated with pCR in patients achieving a complete pathological response in the breast only (OR 0.93; 95% CI 0.18–4.85; p=0.94; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Notably, ER− patients were significantly associated with pCR in studies pooling anthracycline-treated patients (OR 2.78; 95% CI 1.61–4.78; p=0.0002; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The role of the biomarker PR was assessed in Asian breast cancer patients subjected to neoadjuvant chemotherapy (Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "PR was also not associated with treatment response in the adjusted analysis pooling eight studies [54, 56, 61, 94, 97, 102, 103, 106] (OR 1.01; 95% CI 0.64–1.60; p=0.97; Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between treatment response and hormone receptors (HR) comprising ER and PR was assessed in Asian breast cancer patients (Supplementary Figure 7.5 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, analysis with adjusted OR pooling five studies [51, 60, 62, 64, 70] indicated that HR was not significantly associated with treatment response (OR 1.27; 95% CI 0.47–3.45; p=0.64; Supplementary Figure 7.5 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between pCR outcome and HER2 was estimated in Supplementary Figure 7.6 (Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, in an analysis pooling adjusted OR of 12 studies [56, 60, 61, 70, 77, 83, 94, 97, 102, 103, 106, 131], it was observed that HER2+ breast cancer patients were significantly associated with better treatment response (OR 2.29; 95% CI 1.56–3.35; p<0.0001; Supplementary Figure 7.6 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Notably, HER2 was also not associated with pCR in patients achieving a complete pathological response in the breast only (OR 1.96; 95% CI 0.78–4.89; p=0.15; Supplementary Figure 7.6 in Additional file 7) and in anthracycline-treated patients (OR 1.52; 95% CI 0.97–2.40; p=0.07; Supplementary Figure 7.6 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As for Ki-67, an analysis pooling crude OR of eight studies [46, 51, 61, 64, 94, 97, 115, 123] observed that patients with high Ki-67 were significantly associated with better treatment responses (OR 2.63; 95% CI 1.69–4.07; p<0.0001; Supplementary Figure 7.7 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, an analysis of adjusted OR pooling seven studies [12, 46, 51, 54, 94, 97, 110] showed that patients with high Ki-67 were significantly associated with better treatment response (OR 2.63; 95% CI 1.56–4.41; p=0.0003; Supplementary Figure 7.7 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Three biomarkers—ER, HR, and Ki-67—were evaluated by pooling studies reporting their association using hazards ratio (Supplementary Figure 7.8 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As indicated in Fig. 5, subgroup analysis was not conducted for the overall analysis because although the effect is estimated to favour HER2+ significantly, in some studies the true effect may in fact favour HER2−.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Thus, four subsequent subgroup analyses—pooling two studies at each treatment regimen the patients were subjected to—were conducted for the overall PR− vs PR+ (adjusted results) analysis (Supplementary Figure 7.4 in Additional file 7).Discussion\nThere are many options for breast cancer treatment.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Fig. 1 shows how the studies were searched and identified in the various databases and registers.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Finally, 101 studies fulfilled the eligibility criteria and were included in the systematic review and meta-analysis (Fig. 1).Overview of included studies\nAltogether, 19,708 Asian breast cancer patients were gathered from the 101 studies, with an average of 195 patients per study (Supplementary Table 4.1 in Additional file 4).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, the role of molecular subtypes was examined in NAC TA-treated (Figure 2 and Supplementary Figure 7.1 in Additional file 7) and TP-treated (Figures 3 and 4 and Supplementary Figure 7.1 in Additional file 7) breast cancer patients.Taxane-anthracycline (TA) chemotherapy\nOur study first compares the effect of HER2E and luminal subtypes on pCR outcomes in TA-treated patients (Fig. 2A–D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Despite the large number of patients with luminal-like subtypes, our findings significantly associate patients with HER2E subtypes with better pCR outcomes (OR: 4.08; 95% CI; 2.78–6.00; p<0.0001; Fig. 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "When HER2E patients were compared with patients with luminal A subtype, patients with HER2E subtypes were also found to be significantly more likely to achieve pCR (OR 5.27; 95% CI 1.16–23.86; p=0.03; Fig. 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Similarly, when HER2E was analysed against luminal B, HER2E was significantly associated with pCR (OR 2.78; 95% CI 1.42–5.44; p=0.003; Fig. 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Nine studies [34, 35, 71, 80, 84, 95, 98, 100, 113] were pooled, yet our findings still showed that HER2E subtype was significantly associated with pCR outcome in NAC TA-treated patients (OR 3.89; 95% CI 2.69-5.64; p<0.0001; Fig. 2D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Similarly, analyses conducted comparing the effect of TNBC and luminal subtypes on pCR outcome in TA-treated patients (Fig. 2E–H) significantly associate TNBC with better pCR outcome compared to luminal-like (OR 4.45; 95% CI 2.79–7.11; p<0.0001; Fig. 2E), luminal A (OR 11.66; 95% CI 3.64-37.38; p<0.0001; Fig. 2F), luminal B (OR 3.89; 95% CI 2.20–6.87; p<0.0001; Fig. 2G), and luminal, combined (OR 4.59; 95% CI 3.35–6.29; p<0.0001; Fig. 2H).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel E",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel E",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel F",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "To further explore the effect of molecular subtypes on the pCR outcome of NAC TA-treated breast cancer patients, the TNBC subtype was compared to the HER2E subtype revealing that neither was associated with pCR (OR 1.17; 95% CI 0.80-1.70; p=0.43; Supplementary Figure 7.1A in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, an analysis between luminal A and luminal B showed that neither was associated with better pCR outcome when treated with NAC TA (OR 2.47; 95% CI 0.79–7.73; p=0.12; Supplementary Figure 7.1B in Additional file 7).Taxane-platinum (TP) chemotherapy\nIn the analysis pooling three studies [45,64,102] comparing HER2E and luminal-like subtypes, 321 patients were identified with HER2E subtype, and 382 patients were luminal-like.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "When treated with NAC TP, neither HER2E nor luminal-like patients were associated with pCR (OR 1.69; 95% CI 0.70–4.11; p=0.25; Fig. 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "However, in the analysis pooling four studies [41, 69, 97, 115] comparing HER2E and luminal A subtypes, HER2E was significantly associated with pCR outcome (OR 12.11; 95% CI 4.41–33.26; p<0.0001; Fig. 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Similarly, when comparing against luminal B and luminal, combined, HER2E was significantly associated with pCR outcome (OR 5.92; 95% CI 2.59–13.54; p<0.0001; Fig. 3C and OR 3.37; 95% CI 1.66–6.84; p=0.0008; Fig. 3D, respectively).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Substantial heterogeneity was reported for two of the pooled analyses: (1) in studies comparing HER2E and luminal-like (Fig. 3A); and (2) in studies comparing HER2E and luminal, combined (Fig. 3D).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Notably, when HER2E and TNBC patients were compared, neither was associated with pCR (OR 1.46; 95% CI 0.63–3.37; p=0.38; Supplementary Figure 7.1C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "We then compared luminal B and luminal A patients and found that luminal B patients were significantly associated with better pCR outcomes (OR 3.26; 95% CI 1.14–9.26; p=0.03; Fig. 3E).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Similar to NAC TA-treated patients, analyses conducted comparing the effect of TNBC and luminal subtypes on pCR outcome in TP-treated patients also significantly associate TNBC with better pCR outcome compared to luminal A (OR 7.14; 95% CI 2.82–18.04; p<0.0001; Fig. 3F), luminal B (OR 2.19; 95% CI 1.09–4.41; p=0.03; Fig. 3G), and luminal, combined (OR 3.79; 95% CI 1.94–7.40; p<0.0001; Fig. 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Our study compared the effect of chemotherapeutic agents on the pCR outcome in TNBC patients (Fig. 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, the role of biomarkers was investigated in NAC anthracycline-based and taxane-based treated (Fig. 4), TA-treated (Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "4, 5 and 6 and Supplementary Figure 7.1 in Additional file 7), and TP-treated (Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "6 and 7) breast cancer patients.Anthracycline-based and taxane-based chemotherapy\nFour studies [53, 88, 102, 124] were pooled for the effect of ER on pCR outcome in anthracycline-treated patients, where ER was not associated with pCR (OR 1.95; 95% CI 0.98–3.89; p=0.06; Fig. 4C).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Subgroup analysis of ER− vs ER+ pooling studies in the Chinese population only showed that ER− patients were significantly associated with pCR (OR 2.52; 95% CI 1.43–4.44; p=0.001; Fig. 4C), supporting our hypothesis that the observed heterogeneity could be due to the difference in the Asian population.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Our findings showed that PR− patients were significantly associated with pCR (OR 2.40; 95% CI 1.52–3.80; p=0.0002; Fig. 4D).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel D",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Meanwhile, an analysis of three pooled studies [88, 102, 109] on the effect of HER2 on pCR outcome in anthracycline-treated breast cancer patients revealed that patients with HER2− biomarker were significantly more likely to achieve pCR (OR 2.31; 95% CI 1.42–3.75; p=0.0008; Fig. 4E).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel E",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Only one biomarker, HR, was evaluated for its effect on pCR outcome in Asian breast cancer patients treated with taxane-based chemotherapy (Fig. 4F).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Both ER− (OR 3.19; 95% CI 2.15–4.75; p<0.0001; Fig. 4G) and PR− (OR 3.11; 95% CI 2.12-4.56; p<0.0001; Fig. 5A) were significantly associated with pCR outcome in TA-treated patients.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel G",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "In an analysis pooling five studies [60, 81, 98, 100, 127], HR was not associated with pCR outcome (OR 2.38; 95% CI 0.87–6.53; p=0.09; Fig. 5B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "An analysis of nine pooled studies [36, 54, 60, 80–82, 100, 113, 127] showed that HER2+ is significantly associated with pCR (OR 1.78; 95% CI 1.05–3.02; p=0.03; Fig. 5C) with substantial heterogeneity observed between the studies.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "It was observed that nm23-H1− (OR 6.74; 95% CI 2.13–21.30; p=0.001; Fig. 5D) and CK5/6– (OR 1.87; 95% CI 1.03–3.39; p=0.04; Fig. 5E) are significantly associated with pCR.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel D",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel E",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Despite that, EGFR is not associated with pCR outcome in TA-treated patients (OR 2.02; 95% CI 0.28–28.00; p=0.38; Supplementary Figure 7.1D in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The proliferation index biomarker, Ki-67, was evaluated through an analysis of 12 pooled studies [12, 36, 54, 60, 80, 84, 90, 95, 98, 100, 111, 127], revealing significant association between pCR outcome and high Ki-67 (OR 2.98; 95% CI 1.79–4.97; p<0.0001; Fig. 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Five studies [41, 43, 97, 114, 115] and two studies [100,102] were pooled to evaluate the association of ER and PR, and HR, respectively. pCR outcome was significantly associated with ER− (OR 4.91; 95% CI 3.20–7.53; p<0.00001; Fig. 6B), PR− (OR 3.82; 95% CI 2.48–5.90; p<0.00001; Fig. 6C), and HR− (OR 2.71; 95% CI 1.43–5.15; p=0.002; Fig. 6D).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel D",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Ki-67 was evaluated by analysing five pooled studies [47, 57, 97, 114, 115], showing that pCR outcome was not significantly associated with either high Ki-67 or low Ki-67 (OR 2.20; 95% CI 0.74–6.59; p=0.16; Fig. 6E).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel E",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "In the analysis of the effect of HER2 in breast cancer patients pooling five studies [41, 43, 97, 114, 115], pCR outcome was not significantly associated with neither HER2+ nor HER2− (OR 2.44; 95% CI 0.84–7.06; p=0.10; Fig. 7A).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel A",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Our study also evaluated the effect of chemotherapeutic agents on the pCR outcome in Asian breast cancer patients with HER2+ biomarker (Fig. 7B).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, only one gene was analysed for its effect on pCR outcome in Asian breast cancer patients treated with NAC TA (Fig. 7).Taxane-anthracycline (TA) chemotherapy\nFrom the analysis of two studies [100, 106], 564 patients were pooled for PIK3CA analysis.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "It was observed that patients harbouring wtPIK3CA were significantly associated with better pCRoutcomes compared to patients with mtPIK3CA gene (OR: 2.44; 95% CI 1.42–4.19; p=0.001; Fig. 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Process\n\nSearch (n=5746)\nExcluded with reasons [refer to Figure 1 for detailed reasons] (n=5610)\nExcluded after reviewing full-text (n=35)\nIncluded studies (n=101)\n\n\n\nResults\n\nWhere statistically appropriate, studies were pooled.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Open in a new tabPooled reported association\nMeta-analyses of pooled reported association of pCR were evaluated according to molecular classification, genetic variations, and biomarkers characterisation of the Asian breast cancer patients.Molecular classification\nAn adjusted pooled analysis of TNBC against non-TNBC patients showed that TNBC patients were significantly associated with better response when treated with neoadjuvant chemotherapy (OR 3.02; 95% CI 1.54–5.95; p=0.001; Supplementary Figure 7.2A in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "In the adjusted analysis of three [51, 100, 106] and two studies [51, 100] for PIK3CA and TP53 genes, respectively, breast cancer patients harbouring mutation in the PIK3CA gene was associated with worse response (OR 0.64; 95% CI 0.42-0.98; p=0.04; Supplementary Figure 7.2B in Additional file 7) while TP53 gene was not associated with pCR outcome (OR 1.34; 95% CI 0.59–3.05; p=0.49; Supplementary Figure 7.2B in Additional file 7).Biomarkers\nAmongst pooled reported associations of pCR for biomarkers, our study evaluated the effect of Tau, nm23-H1, ER, PR, HR, HER2, and Ki-67 biomarkers in NAC-treated Asian BC patients (Supplementary Figures 7.2–7.8 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "In an adjusted analysis of Tau pooling two studies [61, 83], the result suggests that Tau+ was associated with worse response in the neoadjuvant setting (OR 0.22, 95% CI 0.09–0.54, p=0.0008; Supplementary Figure 7.2C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile in adjusted analysis of nm23-H1 pooling two studies [12, 60], nm23-H1 was not associated with pCR outcome in TA-treated patients (OR 1.56, 95% CI 0.55–4.45, p=0.41; Supplementary Figure 7.2C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between pCR in NAC-treated breast cancer patients and ER was evaluated in Supplementary Figure 7.3 (Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile, adjusted analysis of ER+ vs ER− pooling fourteen studies [54, 56, 61, 68, 71, 72, 83, 94, 97, 102, 103, 106, 112, 131] also showed that ER was not associated with pCR outcome (OR 0.59; 95% CI 0.32–1.08; p=0.09; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile, analyses pooling studies based on the characteristics of the patients showed that ER was not associated with pCR in patients achieving a complete pathological response in the breast only (OR 0.93; 95% CI 0.18–4.85; p=0.94; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Notably, ER− patients were significantly associated with pCR in studies pooling anthracycline-treated patients (OR 2.78; 95% CI 1.61–4.78; p=0.0002; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The role of the biomarker PR was assessed in Asian breast cancer patients subjected to neoadjuvant chemotherapy (Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "PR was also not associated with treatment response in the adjusted analysis pooling eight studies [54, 56, 61, 94, 97, 102, 103, 106] (OR 1.01; 95% CI 0.64–1.60; p=0.97; Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between treatment response and hormone receptors (HR) comprising ER and PR was assessed in Asian breast cancer patients (Supplementary Figure 7.5 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, analysis with adjusted OR pooling five studies [51, 60, 62, 64, 70] indicated that HR was not significantly associated with treatment response (OR 1.27; 95% CI 0.47–3.45; p=0.64; Supplementary Figure 7.5 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between pCR outcome and HER2 was estimated in Supplementary Figure 7.6 (Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, in an analysis pooling adjusted OR of 12 studies [56, 60, 61, 70, 77, 83, 94, 97, 102, 103, 106, 131], it was observed that HER2+ breast cancer patients were significantly associated with better treatment response (OR 2.29; 95% CI 1.56–3.35; p<0.0001; Supplementary Figure 7.6 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Notably, HER2 was also not associated with pCR in patients achieving a complete pathological response in the breast only (OR 1.96; 95% CI 0.78–4.89; p=0.15; Supplementary Figure 7.6 in Additional file 7) and in anthracycline-treated patients (OR 1.52; 95% CI 0.97–2.40; p=0.07; Supplementary Figure 7.6 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As for Ki-67, an analysis pooling crude OR of eight studies [46, 51, 61, 64, 94, 97, 115, 123] observed that patients with high Ki-67 were significantly associated with better treatment responses (OR 2.63; 95% CI 1.69–4.07; p<0.0001; Supplementary Figure 7.7 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, an analysis of adjusted OR pooling seven studies [12, 46, 51, 54, 94, 97, 110] showed that patients with high Ki-67 were significantly associated with better treatment response (OR 2.63; 95% CI 1.56–4.41; p=0.0003; Supplementary Figure 7.7 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Three biomarkers—ER, HR, and Ki-67—were evaluated by pooling studies reporting their association using hazards ratio (Supplementary Figure 7.8 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As indicated in Fig. 5, subgroup analysis was not conducted for the overall analysis because although the effect is estimated to favour HER2+ significantly, in some studies the true effect may in fact favour HER2−.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Thus, four subsequent subgroup analyses—pooling two studies at each treatment regimen the patients were subjected to—were conducted for the overall PR− vs PR+ (adjusted results) analysis (Supplementary Figure 7.4 in Additional file 7).Discussion\nThere are many options for breast cancer treatment.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Fig. 1 shows how the studies were searched and identified in the various databases and registers.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Finally, 101 studies fulfilled the eligibility criteria and were included in the systematic review and meta-analysis (Fig. 1).Overview of included studies\nAltogether, 19,708 Asian breast cancer patients were gathered from the 101 studies, with an average of 195 patients per study (Supplementary Table 4.1 in Additional file 4).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, the role of molecular subtypes was examined in NAC TA-treated (Figure 2 and Supplementary Figure 7.1 in Additional file 7) and TP-treated (Figures 3 and 4 and Supplementary Figure 7.1 in Additional file 7) breast cancer patients.Taxane-anthracycline (TA) chemotherapy\nOur study first compares the effect of HER2E and luminal subtypes on pCR outcomes in TA-treated patients (Fig. 2A–D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Despite the large number of patients with luminal-like subtypes, our findings significantly associate patients with HER2E subtypes with better pCR outcomes (OR: 4.08; 95% CI; 2.78–6.00; p<0.0001; Fig. 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "When HER2E patients were compared with patients with luminal A subtype, patients with HER2E subtypes were also found to be significantly more likely to achieve pCR (OR 5.27; 95% CI 1.16–23.86; p=0.03; Fig. 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Similarly, when HER2E was analysed against luminal B, HER2E was significantly associated with pCR (OR 2.78; 95% CI 1.42–5.44; p=0.003; Fig. 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Nine studies [34, 35, 71, 80, 84, 95, 98, 100, 113] were pooled, yet our findings still showed that HER2E subtype was significantly associated with pCR outcome in NAC TA-treated patients (OR 3.89; 95% CI 2.69-5.64; p<0.0001; Fig. 2D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Similarly, analyses conducted comparing the effect of TNBC and luminal subtypes on pCR outcome in TA-treated patients (Fig. 2E–H) significantly associate TNBC with better pCR outcome compared to luminal-like (OR 4.45; 95% CI 2.79–7.11; p<0.0001; Fig. 2E), luminal A (OR 11.66; 95% CI 3.64-37.38; p<0.0001; Fig. 2F), luminal B (OR 3.89; 95% CI 2.20–6.87; p<0.0001; Fig. 2G), and luminal, combined (OR 4.59; 95% CI 3.35–6.29; p<0.0001; Fig. 2H).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel E",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel E",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel F",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "To further explore the effect of molecular subtypes on the pCR outcome of NAC TA-treated breast cancer patients, the TNBC subtype was compared to the HER2E subtype revealing that neither was associated with pCR (OR 1.17; 95% CI 0.80-1.70; p=0.43; Supplementary Figure 7.1A in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, an analysis between luminal A and luminal B showed that neither was associated with better pCR outcome when treated with NAC TA (OR 2.47; 95% CI 0.79–7.73; p=0.12; Supplementary Figure 7.1B in Additional file 7).Taxane-platinum (TP) chemotherapy\nIn the analysis pooling three studies [45,64,102] comparing HER2E and luminal-like subtypes, 321 patients were identified with HER2E subtype, and 382 patients were luminal-like.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "When treated with NAC TP, neither HER2E nor luminal-like patients were associated with pCR (OR 1.69; 95% CI 0.70–4.11; p=0.25; Fig. 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "However, in the analysis pooling four studies [41, 69, 97, 115] comparing HER2E and luminal A subtypes, HER2E was significantly associated with pCR outcome (OR 12.11; 95% CI 4.41–33.26; p<0.0001; Fig. 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Similarly, when comparing against luminal B and luminal, combined, HER2E was significantly associated with pCR outcome (OR 5.92; 95% CI 2.59–13.54; p<0.0001; Fig. 3C and OR 3.37; 95% CI 1.66–6.84; p=0.0008; Fig. 3D, respectively).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Substantial heterogeneity was reported for two of the pooled analyses: (1) in studies comparing HER2E and luminal-like (Fig. 3A); and (2) in studies comparing HER2E and luminal, combined (Fig. 3D).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Notably, when HER2E and TNBC patients were compared, neither was associated with pCR (OR 1.46; 95% CI 0.63–3.37; p=0.38; Supplementary Figure 7.1C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "We then compared luminal B and luminal A patients and found that luminal B patients were significantly associated with better pCR outcomes (OR 3.26; 95% CI 1.14–9.26; p=0.03; Fig. 3E).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Similar to NAC TA-treated patients, analyses conducted comparing the effect of TNBC and luminal subtypes on pCR outcome in TP-treated patients also significantly associate TNBC with better pCR outcome compared to luminal A (OR 7.14; 95% CI 2.82–18.04; p<0.0001; Fig. 3F), luminal B (OR 2.19; 95% CI 1.09–4.41; p=0.03; Fig. 3G), and luminal, combined (OR 3.79; 95% CI 1.94–7.40; p<0.0001; Fig. 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Our study compared the effect of chemotherapeutic agents on the pCR outcome in TNBC patients (Fig. 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, the role of biomarkers was investigated in NAC anthracycline-based and taxane-based treated (Fig. 4), TA-treated (Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "4, 5 and 6 and Supplementary Figure 7.1 in Additional file 7), and TP-treated (Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "6 and 7) breast cancer patients.Anthracycline-based and taxane-based chemotherapy\nFour studies [53, 88, 102, 124] were pooled for the effect of ER on pCR outcome in anthracycline-treated patients, where ER was not associated with pCR (OR 1.95; 95% CI 0.98–3.89; p=0.06; Fig. 4C).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Subgroup analysis of ER− vs ER+ pooling studies in the Chinese population only showed that ER− patients were significantly associated with pCR (OR 2.52; 95% CI 1.43–4.44; p=0.001; Fig. 4C), supporting our hypothesis that the observed heterogeneity could be due to the difference in the Asian population.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Our findings showed that PR− patients were significantly associated with pCR (OR 2.40; 95% CI 1.52–3.80; p=0.0002; Fig. 4D).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel D",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Meanwhile, an analysis of three pooled studies [88, 102, 109] on the effect of HER2 on pCR outcome in anthracycline-treated breast cancer patients revealed that patients with HER2− biomarker were significantly more likely to achieve pCR (OR 2.31; 95% CI 1.42–3.75; p=0.0008; Fig. 4E).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel E",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Only one biomarker, HR, was evaluated for its effect on pCR outcome in Asian breast cancer patients treated with taxane-based chemotherapy (Fig. 4F).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Both ER− (OR 3.19; 95% CI 2.15–4.75; p<0.0001; Fig. 4G) and PR− (OR 3.11; 95% CI 2.12-4.56; p<0.0001; Fig. 5A) were significantly associated with pCR outcome in TA-treated patients.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel G",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "In an analysis pooling five studies [60, 81, 98, 100, 127], HR was not associated with pCR outcome (OR 2.38; 95% CI 0.87–6.53; p=0.09; Fig. 5B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "An analysis of nine pooled studies [36, 54, 60, 80–82, 100, 113, 127] showed that HER2+ is significantly associated with pCR (OR 1.78; 95% CI 1.05–3.02; p=0.03; Fig. 5C) with substantial heterogeneity observed between the studies.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "It was observed that nm23-H1− (OR 6.74; 95% CI 2.13–21.30; p=0.001; Fig. 5D) and CK5/6– (OR 1.87; 95% CI 1.03–3.39; p=0.04; Fig. 5E) are significantly associated with pCR.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel D",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel E",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Despite that, EGFR is not associated with pCR outcome in TA-treated patients (OR 2.02; 95% CI 0.28–28.00; p=0.38; Supplementary Figure 7.1D in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The proliferation index biomarker, Ki-67, was evaluated through an analysis of 12 pooled studies [12, 36, 54, 60, 80, 84, 90, 95, 98, 100, 111, 127], revealing significant association between pCR outcome and high Ki-67 (OR 2.98; 95% CI 1.79–4.97; p<0.0001; Fig. 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Five studies [41, 43, 97, 114, 115] and two studies [100,102] were pooled to evaluate the association of ER and PR, and HR, respectively. pCR outcome was significantly associated with ER− (OR 4.91; 95% CI 3.20–7.53; p<0.00001; Fig. 6B), PR− (OR 3.82; 95% CI 2.48–5.90; p<0.00001; Fig. 6C), and HR− (OR 2.71; 95% CI 1.43–5.15; p=0.002; Fig. 6D).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel D",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Ki-67 was evaluated by analysing five pooled studies [47, 57, 97, 114, 115], showing that pCR outcome was not significantly associated with either high Ki-67 or low Ki-67 (OR 2.20; 95% CI 0.74–6.59; p=0.16; Fig. 6E).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel E",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "In the analysis of the effect of HER2 in breast cancer patients pooling five studies [41, 43, 97, 114, 115], pCR outcome was not significantly associated with neither HER2+ nor HER2− (OR 2.44; 95% CI 0.84–7.06; p=0.10; Fig. 7A).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel A",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Our study also evaluated the effect of chemotherapeutic agents on the pCR outcome in Asian breast cancer patients with HER2+ biomarker (Fig. 7B).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, only one gene was analysed for its effect on pCR outcome in Asian breast cancer patients treated with NAC TA (Fig. 7).Taxane-anthracycline (TA) chemotherapy\nFrom the analysis of two studies [100, 106], 564 patients were pooled for PIK3CA analysis.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "It was observed that patients harbouring wtPIK3CA were significantly associated with better pCRoutcomes compared to patients with mtPIK3CA gene (OR: 2.44; 95% CI 1.42–4.19; p=0.001; Fig. 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Process\n\nSearch (n=5746)\nExcluded with reasons [refer to Figure 1 for detailed reasons] (n=5610)\nExcluded after reviewing full-text (n=35)\nIncluded studies (n=101)\n\n\n\nResults\n\nWhere statistically appropriate, studies were pooled.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Open in a new tabPooled reported association\nMeta-analyses of pooled reported association of pCR were evaluated according to molecular classification, genetic variations, and biomarkers characterisation of the Asian breast cancer patients.Molecular classification\nAn adjusted pooled analysis of TNBC against non-TNBC patients showed that TNBC patients were significantly associated with better response when treated with neoadjuvant chemotherapy (OR 3.02; 95% CI 1.54–5.95; p=0.001; Supplementary Figure 7.2A in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "In the adjusted analysis of three [51, 100, 106] and two studies [51, 100] for PIK3CA and TP53 genes, respectively, breast cancer patients harbouring mutation in the PIK3CA gene was associated with worse response (OR 0.64; 95% CI 0.42-0.98; p=0.04; Supplementary Figure 7.2B in Additional file 7) while TP53 gene was not associated with pCR outcome (OR 1.34; 95% CI 0.59–3.05; p=0.49; Supplementary Figure 7.2B in Additional file 7).Biomarkers\nAmongst pooled reported associations of pCR for biomarkers, our study evaluated the effect of Tau, nm23-H1, ER, PR, HR, HER2, and Ki-67 biomarkers in NAC-treated Asian BC patients (Supplementary Figures 7.2–7.8 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "In an adjusted analysis of Tau pooling two studies [61, 83], the result suggests that Tau+ was associated with worse response in the neoadjuvant setting (OR 0.22, 95% CI 0.09–0.54, p=0.0008; Supplementary Figure 7.2C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile in adjusted analysis of nm23-H1 pooling two studies [12, 60], nm23-H1 was not associated with pCR outcome in TA-treated patients (OR 1.56, 95% CI 0.55–4.45, p=0.41; Supplementary Figure 7.2C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between pCR in NAC-treated breast cancer patients and ER was evaluated in Supplementary Figure 7.3 (Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile, adjusted analysis of ER+ vs ER− pooling fourteen studies [54, 56, 61, 68, 71, 72, 83, 94, 97, 102, 103, 106, 112, 131] also showed that ER was not associated with pCR outcome (OR 0.59; 95% CI 0.32–1.08; p=0.09; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile, analyses pooling studies based on the characteristics of the patients showed that ER was not associated with pCR in patients achieving a complete pathological response in the breast only (OR 0.93; 95% CI 0.18–4.85; p=0.94; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Notably, ER− patients were significantly associated with pCR in studies pooling anthracycline-treated patients (OR 2.78; 95% CI 1.61–4.78; p=0.0002; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The role of the biomarker PR was assessed in Asian breast cancer patients subjected to neoadjuvant chemotherapy (Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "PR was also not associated with treatment response in the adjusted analysis pooling eight studies [54, 56, 61, 94, 97, 102, 103, 106] (OR 1.01; 95% CI 0.64–1.60; p=0.97; Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between treatment response and hormone receptors (HR) comprising ER and PR was assessed in Asian breast cancer patients (Supplementary Figure 7.5 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, analysis with adjusted OR pooling five studies [51, 60, 62, 64, 70] indicated that HR was not significantly associated with treatment response (OR 1.27; 95% CI 0.47–3.45; p=0.64; Supplementary Figure 7.5 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between pCR outcome and HER2 was estimated in Supplementary Figure 7.6 (Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, in an analysis pooling adjusted OR of 12 studies [56, 60, 61, 70, 77, 83, 94, 97, 102, 103, 106, 131], it was observed that HER2+ breast cancer patients were significantly associated with better treatment response (OR 2.29; 95% CI 1.56–3.35; p<0.0001; Supplementary Figure 7.6 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Notably, HER2 was also not associated with pCR in patients achieving a complete pathological response in the breast only (OR 1.96; 95% CI 0.78–4.89; p=0.15; Supplementary Figure 7.6 in Additional file 7) and in anthracycline-treated patients (OR 1.52; 95% CI 0.97–2.40; p=0.07; Supplementary Figure 7.6 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As for Ki-67, an analysis pooling crude OR of eight studies [46, 51, 61, 64, 94, 97, 115, 123] observed that patients with high Ki-67 were significantly associated with better treatment responses (OR 2.63; 95% CI 1.69–4.07; p<0.0001; Supplementary Figure 7.7 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, an analysis of adjusted OR pooling seven studies [12, 46, 51, 54, 94, 97, 110] showed that patients with high Ki-67 were significantly associated with better treatment response (OR 2.63; 95% CI 1.56–4.41; p=0.0003; Supplementary Figure 7.7 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Three biomarkers—ER, HR, and Ki-67—were evaluated by pooling studies reporting their association using hazards ratio (Supplementary Figure 7.8 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As indicated in Fig. 5, subgroup analysis was not conducted for the overall analysis because although the effect is estimated to favour HER2+ significantly, in some studies the true effect may in fact favour HER2−.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Thus, four subsequent subgroup analyses—pooling two studies at each treatment regimen the patients were subjected to—were conducted for the overall PR− vs PR+ (adjusted results) analysis (Supplementary Figure 7.4 in Additional file 7).Discussion\nThere are many options for breast cancer treatment.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Fig. 1 shows how the studies were searched and identified in the various databases and registers.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Finally, 101 studies fulfilled the eligibility criteria and were included in the systematic review and meta-analysis (Fig. 1).Overview of included studies\nAltogether, 19,708 Asian breast cancer patients were gathered from the 101 studies, with an average of 195 patients per study (Supplementary Table 4.1 in Additional file 4).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, the role of molecular subtypes was examined in NAC TA-treated (Figure 2 and Supplementary Figure 7.1 in Additional file 7) and TP-treated (Figures 3 and 4 and Supplementary Figure 7.1 in Additional file 7) breast cancer patients.Taxane-anthracycline (TA) chemotherapy\nOur study first compares the effect of HER2E and luminal subtypes on pCR outcomes in TA-treated patients (Fig. 2A–D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Despite the large number of patients with luminal-like subtypes, our findings significantly associate patients with HER2E subtypes with better pCR outcomes (OR: 4.08; 95% CI; 2.78–6.00; p<0.0001; Fig. 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "When HER2E patients were compared with patients with luminal A subtype, patients with HER2E subtypes were also found to be significantly more likely to achieve pCR (OR 5.27; 95% CI 1.16–23.86; p=0.03; Fig. 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Similarly, when HER2E was analysed against luminal B, HER2E was significantly associated with pCR (OR 2.78; 95% CI 1.42–5.44; p=0.003; Fig. 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Nine studies [34, 35, 71, 80, 84, 95, 98, 100, 113] were pooled, yet our findings still showed that HER2E subtype was significantly associated with pCR outcome in NAC TA-treated patients (OR 3.89; 95% CI 2.69-5.64; p<0.0001; Fig. 2D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Similarly, analyses conducted comparing the effect of TNBC and luminal subtypes on pCR outcome in TA-treated patients (Fig. 2E–H) significantly associate TNBC with better pCR outcome compared to luminal-like (OR 4.45; 95% CI 2.79–7.11; p<0.0001; Fig. 2E), luminal A (OR 11.66; 95% CI 3.64-37.38; p<0.0001; Fig. 2F), luminal B (OR 3.89; 95% CI 2.20–6.87; p<0.0001; Fig. 2G), and luminal, combined (OR 4.59; 95% CI 3.35–6.29; p<0.0001; Fig. 2H).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel E",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel E",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel F",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "To further explore the effect of molecular subtypes on the pCR outcome of NAC TA-treated breast cancer patients, the TNBC subtype was compared to the HER2E subtype revealing that neither was associated with pCR (OR 1.17; 95% CI 0.80-1.70; p=0.43; Supplementary Figure 7.1A in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, an analysis between luminal A and luminal B showed that neither was associated with better pCR outcome when treated with NAC TA (OR 2.47; 95% CI 0.79–7.73; p=0.12; Supplementary Figure 7.1B in Additional file 7).Taxane-platinum (TP) chemotherapy\nIn the analysis pooling three studies [45,64,102] comparing HER2E and luminal-like subtypes, 321 patients were identified with HER2E subtype, and 382 patients were luminal-like.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "When treated with NAC TP, neither HER2E nor luminal-like patients were associated with pCR (OR 1.69; 95% CI 0.70–4.11; p=0.25; Fig. 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "However, in the analysis pooling four studies [41, 69, 97, 115] comparing HER2E and luminal A subtypes, HER2E was significantly associated with pCR outcome (OR 12.11; 95% CI 4.41–33.26; p<0.0001; Fig. 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Similarly, when comparing against luminal B and luminal, combined, HER2E was significantly associated with pCR outcome (OR 5.92; 95% CI 2.59–13.54; p<0.0001; Fig. 3C and OR 3.37; 95% CI 1.66–6.84; p=0.0008; Fig. 3D, respectively).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Substantial heterogeneity was reported for two of the pooled analyses: (1) in studies comparing HER2E and luminal-like (Fig. 3A); and (2) in studies comparing HER2E and luminal, combined (Fig. 3D).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Notably, when HER2E and TNBC patients were compared, neither was associated with pCR (OR 1.46; 95% CI 0.63–3.37; p=0.38; Supplementary Figure 7.1C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "We then compared luminal B and luminal A patients and found that luminal B patients were significantly associated with better pCR outcomes (OR 3.26; 95% CI 1.14–9.26; p=0.03; Fig. 3E).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Similar to NAC TA-treated patients, analyses conducted comparing the effect of TNBC and luminal subtypes on pCR outcome in TP-treated patients also significantly associate TNBC with better pCR outcome compared to luminal A (OR 7.14; 95% CI 2.82–18.04; p<0.0001; Fig. 3F), luminal B (OR 2.19; 95% CI 1.09–4.41; p=0.03; Fig. 3G), and luminal, combined (OR 3.79; 95% CI 1.94–7.40; p<0.0001; Fig. 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Our study compared the effect of chemotherapeutic agents on the pCR outcome in TNBC patients (Fig. 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, the role of biomarkers was investigated in NAC anthracycline-based and taxane-based treated (Fig. 4), TA-treated (Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "4, 5 and 6 and Supplementary Figure 7.1 in Additional file 7), and TP-treated (Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "6 and 7) breast cancer patients.Anthracycline-based and taxane-based chemotherapy\nFour studies [53, 88, 102, 124] were pooled for the effect of ER on pCR outcome in anthracycline-treated patients, where ER was not associated with pCR (OR 1.95; 95% CI 0.98–3.89; p=0.06; Fig. 4C).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Subgroup analysis of ER− vs ER+ pooling studies in the Chinese population only showed that ER− patients were significantly associated with pCR (OR 2.52; 95% CI 1.43–4.44; p=0.001; Fig. 4C), supporting our hypothesis that the observed heterogeneity could be due to the difference in the Asian population.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Our findings showed that PR− patients were significantly associated with pCR (OR 2.40; 95% CI 1.52–3.80; p=0.0002; Fig. 4D).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel D",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Meanwhile, an analysis of three pooled studies [88, 102, 109] on the effect of HER2 on pCR outcome in anthracycline-treated breast cancer patients revealed that patients with HER2− biomarker were significantly more likely to achieve pCR (OR 2.31; 95% CI 1.42–3.75; p=0.0008; Fig. 4E).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel E",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Only one biomarker, HR, was evaluated for its effect on pCR outcome in Asian breast cancer patients treated with taxane-based chemotherapy (Fig. 4F).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Both ER− (OR 3.19; 95% CI 2.15–4.75; p<0.0001; Fig. 4G) and PR− (OR 3.11; 95% CI 2.12-4.56; p<0.0001; Fig. 5A) were significantly associated with pCR outcome in TA-treated patients.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel G",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "In an analysis pooling five studies [60, 81, 98, 100, 127], HR was not associated with pCR outcome (OR 2.38; 95% CI 0.87–6.53; p=0.09; Fig. 5B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "An analysis of nine pooled studies [36, 54, 60, 80–82, 100, 113, 127] showed that HER2+ is significantly associated with pCR (OR 1.78; 95% CI 1.05–3.02; p=0.03; Fig. 5C) with substantial heterogeneity observed between the studies.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "It was observed that nm23-H1− (OR 6.74; 95% CI 2.13–21.30; p=0.001; Fig. 5D) and CK5/6– (OR 1.87; 95% CI 1.03–3.39; p=0.04; Fig. 5E) are significantly associated with pCR.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel D",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel E",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Despite that, EGFR is not associated with pCR outcome in TA-treated patients (OR 2.02; 95% CI 0.28–28.00; p=0.38; Supplementary Figure 7.1D in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The proliferation index biomarker, Ki-67, was evaluated through an analysis of 12 pooled studies [12, 36, 54, 60, 80, 84, 90, 95, 98, 100, 111, 127], revealing significant association between pCR outcome and high Ki-67 (OR 2.98; 95% CI 1.79–4.97; p<0.0001; Fig. 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Five studies [41, 43, 97, 114, 115] and two studies [100,102] were pooled to evaluate the association of ER and PR, and HR, respectively. pCR outcome was significantly associated with ER− (OR 4.91; 95% CI 3.20–7.53; p<0.00001; Fig. 6B), PR− (OR 3.82; 95% CI 2.48–5.90; p<0.00001; Fig. 6C), and HR− (OR 2.71; 95% CI 1.43–5.15; p=0.002; Fig. 6D).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel D",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Ki-67 was evaluated by analysing five pooled studies [47, 57, 97, 114, 115], showing that pCR outcome was not significantly associated with either high Ki-67 or low Ki-67 (OR 2.20; 95% CI 0.74–6.59; p=0.16; Fig. 6E).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel E",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "In the analysis of the effect of HER2 in breast cancer patients pooling five studies [41, 43, 97, 114, 115], pCR outcome was not significantly associated with neither HER2+ nor HER2− (OR 2.44; 95% CI 0.84–7.06; p=0.10; Fig. 7A).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel A",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Our study also evaluated the effect of chemotherapeutic agents on the pCR outcome in Asian breast cancer patients with HER2+ biomarker (Fig. 7B).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, only one gene was analysed for its effect on pCR outcome in Asian breast cancer patients treated with NAC TA (Fig. 7).Taxane-anthracycline (TA) chemotherapy\nFrom the analysis of two studies [100, 106], 564 patients were pooled for PIK3CA analysis.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "It was observed that patients harbouring wtPIK3CA were significantly associated with better pCRoutcomes compared to patients with mtPIK3CA gene (OR: 2.44; 95% CI 1.42–4.19; p=0.001; Fig. 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Process\n\nSearch (n=5746)\nExcluded with reasons [refer to Figure 1 for detailed reasons] (n=5610)\nExcluded after reviewing full-text (n=35)\nIncluded studies (n=101)\n\n\n\nResults\n\nWhere statistically appropriate, studies were pooled.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Open in a new tabPooled reported association\nMeta-analyses of pooled reported association of pCR were evaluated according to molecular classification, genetic variations, and biomarkers characterisation of the Asian breast cancer patients.Molecular classification\nAn adjusted pooled analysis of TNBC against non-TNBC patients showed that TNBC patients were significantly associated with better response when treated with neoadjuvant chemotherapy (OR 3.02; 95% CI 1.54–5.95; p=0.001; Supplementary Figure 7.2A in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "In the adjusted analysis of three [51, 100, 106] and two studies [51, 100] for PIK3CA and TP53 genes, respectively, breast cancer patients harbouring mutation in the PIK3CA gene was associated with worse response (OR 0.64; 95% CI 0.42-0.98; p=0.04; Supplementary Figure 7.2B in Additional file 7) while TP53 gene was not associated with pCR outcome (OR 1.34; 95% CI 0.59–3.05; p=0.49; Supplementary Figure 7.2B in Additional file 7).Biomarkers\nAmongst pooled reported associations of pCR for biomarkers, our study evaluated the effect of Tau, nm23-H1, ER, PR, HR, HER2, and Ki-67 biomarkers in NAC-treated Asian BC patients (Supplementary Figures 7.2–7.8 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "In an adjusted analysis of Tau pooling two studies [61, 83], the result suggests that Tau+ was associated with worse response in the neoadjuvant setting (OR 0.22, 95% CI 0.09–0.54, p=0.0008; Supplementary Figure 7.2C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile in adjusted analysis of nm23-H1 pooling two studies [12, 60], nm23-H1 was not associated with pCR outcome in TA-treated patients (OR 1.56, 95% CI 0.55–4.45, p=0.41; Supplementary Figure 7.2C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between pCR in NAC-treated breast cancer patients and ER was evaluated in Supplementary Figure 7.3 (Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile, adjusted analysis of ER+ vs ER− pooling fourteen studies [54, 56, 61, 68, 71, 72, 83, 94, 97, 102, 103, 106, 112, 131] also showed that ER was not associated with pCR outcome (OR 0.59; 95% CI 0.32–1.08; p=0.09; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile, analyses pooling studies based on the characteristics of the patients showed that ER was not associated with pCR in patients achieving a complete pathological response in the breast only (OR 0.93; 95% CI 0.18–4.85; p=0.94; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Notably, ER− patients were significantly associated with pCR in studies pooling anthracycline-treated patients (OR 2.78; 95% CI 1.61–4.78; p=0.0002; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The role of the biomarker PR was assessed in Asian breast cancer patients subjected to neoadjuvant chemotherapy (Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "PR was also not associated with treatment response in the adjusted analysis pooling eight studies [54, 56, 61, 94, 97, 102, 103, 106] (OR 1.01; 95% CI 0.64–1.60; p=0.97; Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between treatment response and hormone receptors (HR) comprising ER and PR was assessed in Asian breast cancer patients (Supplementary Figure 7.5 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, analysis with adjusted OR pooling five studies [51, 60, 62, 64, 70] indicated that HR was not significantly associated with treatment response (OR 1.27; 95% CI 0.47–3.45; p=0.64; Supplementary Figure 7.5 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between pCR outcome and HER2 was estimated in Supplementary Figure 7.6 (Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, in an analysis pooling adjusted OR of 12 studies [56, 60, 61, 70, 77, 83, 94, 97, 102, 103, 106, 131], it was observed that HER2+ breast cancer patients were significantly associated with better treatment response (OR 2.29; 95% CI 1.56–3.35; p<0.0001; Supplementary Figure 7.6 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Notably, HER2 was also not associated with pCR in patients achieving a complete pathological response in the breast only (OR 1.96; 95% CI 0.78–4.89; p=0.15; Supplementary Figure 7.6 in Additional file 7) and in anthracycline-treated patients (OR 1.52; 95% CI 0.97–2.40; p=0.07; Supplementary Figure 7.6 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As for Ki-67, an analysis pooling crude OR of eight studies [46, 51, 61, 64, 94, 97, 115, 123] observed that patients with high Ki-67 were significantly associated with better treatment responses (OR 2.63; 95% CI 1.69–4.07; p<0.0001; Supplementary Figure 7.7 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, an analysis of adjusted OR pooling seven studies [12, 46, 51, 54, 94, 97, 110] showed that patients with high Ki-67 were significantly associated with better treatment response (OR 2.63; 95% CI 1.56–4.41; p=0.0003; Supplementary Figure 7.7 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Three biomarkers—ER, HR, and Ki-67—were evaluated by pooling studies reporting their association using hazards ratio (Supplementary Figure 7.8 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As indicated in Fig. 5, subgroup analysis was not conducted for the overall analysis because although the effect is estimated to favour HER2+ significantly, in some studies the true effect may in fact favour HER2−.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Thus, four subsequent subgroup analyses—pooling two studies at each treatment regimen the patients were subjected to—were conducted for the overall PR− vs PR+ (adjusted results) analysis (Supplementary Figure 7.4 in Additional file 7).Discussion\nThere are many options for breast cancer treatment.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Fig. 1 shows how the studies were searched and identified in the various databases and registers.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Finally, 101 studies fulfilled the eligibility criteria and were included in the systematic review and meta-analysis (Fig. 1).Overview of included studies\nAltogether, 19,708 Asian breast cancer patients were gathered from the 101 studies, with an average of 195 patients per study (Supplementary Table 4.1 in Additional file 4).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, the role of molecular subtypes was examined in NAC TA-treated (Figure 2 and Supplementary Figure 7.1 in Additional file 7) and TP-treated (Figures 3 and 4 and Supplementary Figure 7.1 in Additional file 7) breast cancer patients.Taxane-anthracycline (TA) chemotherapy\nOur study first compares the effect of HER2E and luminal subtypes on pCR outcomes in TA-treated patients (Fig. 2A–D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Despite the large number of patients with luminal-like subtypes, our findings significantly associate patients with HER2E subtypes with better pCR outcomes (OR: 4.08; 95% CI; 2.78–6.00; p<0.0001; Fig. 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "When HER2E patients were compared with patients with luminal A subtype, patients with HER2E subtypes were also found to be significantly more likely to achieve pCR (OR 5.27; 95% CI 1.16–23.86; p=0.03; Fig. 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Similarly, when HER2E was analysed against luminal B, HER2E was significantly associated with pCR (OR 2.78; 95% CI 1.42–5.44; p=0.003; Fig. 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Nine studies [34, 35, 71, 80, 84, 95, 98, 100, 113] were pooled, yet our findings still showed that HER2E subtype was significantly associated with pCR outcome in NAC TA-treated patients (OR 3.89; 95% CI 2.69-5.64; p<0.0001; Fig. 2D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Similarly, analyses conducted comparing the effect of TNBC and luminal subtypes on pCR outcome in TA-treated patients (Fig. 2E–H) significantly associate TNBC with better pCR outcome compared to luminal-like (OR 4.45; 95% CI 2.79–7.11; p<0.0001; Fig. 2E), luminal A (OR 11.66; 95% CI 3.64-37.38; p<0.0001; Fig. 2F), luminal B (OR 3.89; 95% CI 2.20–6.87; p<0.0001; Fig. 2G), and luminal, combined (OR 4.59; 95% CI 3.35–6.29; p<0.0001; Fig. 2H).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel E",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel E",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel F",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "To further explore the effect of molecular subtypes on the pCR outcome of NAC TA-treated breast cancer patients, the TNBC subtype was compared to the HER2E subtype revealing that neither was associated with pCR (OR 1.17; 95% CI 0.80-1.70; p=0.43; Supplementary Figure 7.1A in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, an analysis between luminal A and luminal B showed that neither was associated with better pCR outcome when treated with NAC TA (OR 2.47; 95% CI 0.79–7.73; p=0.12; Supplementary Figure 7.1B in Additional file 7).Taxane-platinum (TP) chemotherapy\nIn the analysis pooling three studies [45,64,102] comparing HER2E and luminal-like subtypes, 321 patients were identified with HER2E subtype, and 382 patients were luminal-like.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "When treated with NAC TP, neither HER2E nor luminal-like patients were associated with pCR (OR 1.69; 95% CI 0.70–4.11; p=0.25; Fig. 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "However, in the analysis pooling four studies [41, 69, 97, 115] comparing HER2E and luminal A subtypes, HER2E was significantly associated with pCR outcome (OR 12.11; 95% CI 4.41–33.26; p<0.0001; Fig. 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Similarly, when comparing against luminal B and luminal, combined, HER2E was significantly associated with pCR outcome (OR 5.92; 95% CI 2.59–13.54; p<0.0001; Fig. 3C and OR 3.37; 95% CI 1.66–6.84; p=0.0008; Fig. 3D, respectively).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Substantial heterogeneity was reported for two of the pooled analyses: (1) in studies comparing HER2E and luminal-like (Fig. 3A); and (2) in studies comparing HER2E and luminal, combined (Fig. 3D).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Notably, when HER2E and TNBC patients were compared, neither was associated with pCR (OR 1.46; 95% CI 0.63–3.37; p=0.38; Supplementary Figure 7.1C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "We then compared luminal B and luminal A patients and found that luminal B patients were significantly associated with better pCR outcomes (OR 3.26; 95% CI 1.14–9.26; p=0.03; Fig. 3E).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Similar to NAC TA-treated patients, analyses conducted comparing the effect of TNBC and luminal subtypes on pCR outcome in TP-treated patients also significantly associate TNBC with better pCR outcome compared to luminal A (OR 7.14; 95% CI 2.82–18.04; p<0.0001; Fig. 3F), luminal B (OR 2.19; 95% CI 1.09–4.41; p=0.03; Fig. 3G), and luminal, combined (OR 3.79; 95% CI 1.94–7.40; p<0.0001; Fig. 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Our study compared the effect of chemotherapeutic agents on the pCR outcome in TNBC patients (Fig. 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, the role of biomarkers was investigated in NAC anthracycline-based and taxane-based treated (Fig. 4), TA-treated (Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "4, 5 and 6 and Supplementary Figure 7.1 in Additional file 7), and TP-treated (Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "6 and 7) breast cancer patients.Anthracycline-based and taxane-based chemotherapy\nFour studies [53, 88, 102, 124] were pooled for the effect of ER on pCR outcome in anthracycline-treated patients, where ER was not associated with pCR (OR 1.95; 95% CI 0.98–3.89; p=0.06; Fig. 4C).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Subgroup analysis of ER− vs ER+ pooling studies in the Chinese population only showed that ER− patients were significantly associated with pCR (OR 2.52; 95% CI 1.43–4.44; p=0.001; Fig. 4C), supporting our hypothesis that the observed heterogeneity could be due to the difference in the Asian population.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Our findings showed that PR− patients were significantly associated with pCR (OR 2.40; 95% CI 1.52–3.80; p=0.0002; Fig. 4D).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel D",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Meanwhile, an analysis of three pooled studies [88, 102, 109] on the effect of HER2 on pCR outcome in anthracycline-treated breast cancer patients revealed that patients with HER2− biomarker were significantly more likely to achieve pCR (OR 2.31; 95% CI 1.42–3.75; p=0.0008; Fig. 4E).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel E",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Only one biomarker, HR, was evaluated for its effect on pCR outcome in Asian breast cancer patients treated with taxane-based chemotherapy (Fig. 4F).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Both ER− (OR 3.19; 95% CI 2.15–4.75; p<0.0001; Fig. 4G) and PR− (OR 3.11; 95% CI 2.12-4.56; p<0.0001; Fig. 5A) were significantly associated with pCR outcome in TA-treated patients.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel G",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "In an analysis pooling five studies [60, 81, 98, 100, 127], HR was not associated with pCR outcome (OR 2.38; 95% CI 0.87–6.53; p=0.09; Fig. 5B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "An analysis of nine pooled studies [36, 54, 60, 80–82, 100, 113, 127] showed that HER2+ is significantly associated with pCR (OR 1.78; 95% CI 1.05–3.02; p=0.03; Fig. 5C) with substantial heterogeneity observed between the studies.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "It was observed that nm23-H1− (OR 6.74; 95% CI 2.13–21.30; p=0.001; Fig. 5D) and CK5/6– (OR 1.87; 95% CI 1.03–3.39; p=0.04; Fig. 5E) are significantly associated with pCR.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel D",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel E",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Despite that, EGFR is not associated with pCR outcome in TA-treated patients (OR 2.02; 95% CI 0.28–28.00; p=0.38; Supplementary Figure 7.1D in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The proliferation index biomarker, Ki-67, was evaluated through an analysis of 12 pooled studies [12, 36, 54, 60, 80, 84, 90, 95, 98, 100, 111, 127], revealing significant association between pCR outcome and high Ki-67 (OR 2.98; 95% CI 1.79–4.97; p<0.0001; Fig. 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Five studies [41, 43, 97, 114, 115] and two studies [100,102] were pooled to evaluate the association of ER and PR, and HR, respectively. pCR outcome was significantly associated with ER− (OR 4.91; 95% CI 3.20–7.53; p<0.00001; Fig. 6B), PR− (OR 3.82; 95% CI 2.48–5.90; p<0.00001; Fig. 6C), and HR− (OR 2.71; 95% CI 1.43–5.15; p=0.002; Fig. 6D).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel D",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Ki-67 was evaluated by analysing five pooled studies [47, 57, 97, 114, 115], showing that pCR outcome was not significantly associated with either high Ki-67 or low Ki-67 (OR 2.20; 95% CI 0.74–6.59; p=0.16; Fig. 6E).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel E",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "In the analysis of the effect of HER2 in breast cancer patients pooling five studies [41, 43, 97, 114, 115], pCR outcome was not significantly associated with neither HER2+ nor HER2− (OR 2.44; 95% CI 0.84–7.06; p=0.10; Fig. 7A).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel A",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Our study also evaluated the effect of chemotherapeutic agents on the pCR outcome in Asian breast cancer patients with HER2+ biomarker (Fig. 7B).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, only one gene was analysed for its effect on pCR outcome in Asian breast cancer patients treated with NAC TA (Fig. 7).Taxane-anthracycline (TA) chemotherapy\nFrom the analysis of two studies [100, 106], 564 patients were pooled for PIK3CA analysis.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "It was observed that patients harbouring wtPIK3CA were significantly associated with better pCRoutcomes compared to patients with mtPIK3CA gene (OR: 2.44; 95% CI 1.42–4.19; p=0.001; Fig. 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Process\n\nSearch (n=5746)\nExcluded with reasons [refer to Figure 1 for detailed reasons] (n=5610)\nExcluded after reviewing full-text (n=35)\nIncluded studies (n=101)\n\n\n\nResults\n\nWhere statistically appropriate, studies were pooled.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Open in a new tabPooled reported association\nMeta-analyses of pooled reported association of pCR were evaluated according to molecular classification, genetic variations, and biomarkers characterisation of the Asian breast cancer patients.Molecular classification\nAn adjusted pooled analysis of TNBC against non-TNBC patients showed that TNBC patients were significantly associated with better response when treated with neoadjuvant chemotherapy (OR 3.02; 95% CI 1.54–5.95; p=0.001; Supplementary Figure 7.2A in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "In the adjusted analysis of three [51, 100, 106] and two studies [51, 100] for PIK3CA and TP53 genes, respectively, breast cancer patients harbouring mutation in the PIK3CA gene was associated with worse response (OR 0.64; 95% CI 0.42-0.98; p=0.04; Supplementary Figure 7.2B in Additional file 7) while TP53 gene was not associated with pCR outcome (OR 1.34; 95% CI 0.59–3.05; p=0.49; Supplementary Figure 7.2B in Additional file 7).Biomarkers\nAmongst pooled reported associations of pCR for biomarkers, our study evaluated the effect of Tau, nm23-H1, ER, PR, HR, HER2, and Ki-67 biomarkers in NAC-treated Asian BC patients (Supplementary Figures 7.2–7.8 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "In an adjusted analysis of Tau pooling two studies [61, 83], the result suggests that Tau+ was associated with worse response in the neoadjuvant setting (OR 0.22, 95% CI 0.09–0.54, p=0.0008; Supplementary Figure 7.2C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile in adjusted analysis of nm23-H1 pooling two studies [12, 60], nm23-H1 was not associated with pCR outcome in TA-treated patients (OR 1.56, 95% CI 0.55–4.45, p=0.41; Supplementary Figure 7.2C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between pCR in NAC-treated breast cancer patients and ER was evaluated in Supplementary Figure 7.3 (Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile, adjusted analysis of ER+ vs ER− pooling fourteen studies [54, 56, 61, 68, 71, 72, 83, 94, 97, 102, 103, 106, 112, 131] also showed that ER was not associated with pCR outcome (OR 0.59; 95% CI 0.32–1.08; p=0.09; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile, analyses pooling studies based on the characteristics of the patients showed that ER was not associated with pCR in patients achieving a complete pathological response in the breast only (OR 0.93; 95% CI 0.18–4.85; p=0.94; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Notably, ER− patients were significantly associated with pCR in studies pooling anthracycline-treated patients (OR 2.78; 95% CI 1.61–4.78; p=0.0002; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The role of the biomarker PR was assessed in Asian breast cancer patients subjected to neoadjuvant chemotherapy (Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "PR was also not associated with treatment response in the adjusted analysis pooling eight studies [54, 56, 61, 94, 97, 102, 103, 106] (OR 1.01; 95% CI 0.64–1.60; p=0.97; Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between treatment response and hormone receptors (HR) comprising ER and PR was assessed in Asian breast cancer patients (Supplementary Figure 7.5 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, analysis with adjusted OR pooling five studies [51, 60, 62, 64, 70] indicated that HR was not significantly associated with treatment response (OR 1.27; 95% CI 0.47–3.45; p=0.64; Supplementary Figure 7.5 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between pCR outcome and HER2 was estimated in Supplementary Figure 7.6 (Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, in an analysis pooling adjusted OR of 12 studies [56, 60, 61, 70, 77, 83, 94, 97, 102, 103, 106, 131], it was observed that HER2+ breast cancer patients were significantly associated with better treatment response (OR 2.29; 95% CI 1.56–3.35; p<0.0001; Supplementary Figure 7.6 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Notably, HER2 was also not associated with pCR in patients achieving a complete pathological response in the breast only (OR 1.96; 95% CI 0.78–4.89; p=0.15; Supplementary Figure 7.6 in Additional file 7) and in anthracycline-treated patients (OR 1.52; 95% CI 0.97–2.40; p=0.07; Supplementary Figure 7.6 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As for Ki-67, an analysis pooling crude OR of eight studies [46, 51, 61, 64, 94, 97, 115, 123] observed that patients with high Ki-67 were significantly associated with better treatment responses (OR 2.63; 95% CI 1.69–4.07; p<0.0001; Supplementary Figure 7.7 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, an analysis of adjusted OR pooling seven studies [12, 46, 51, 54, 94, 97, 110] showed that patients with high Ki-67 were significantly associated with better treatment response (OR 2.63; 95% CI 1.56–4.41; p=0.0003; Supplementary Figure 7.7 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Three biomarkers—ER, HR, and Ki-67—were evaluated by pooling studies reporting their association using hazards ratio (Supplementary Figure 7.8 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As indicated in Fig. 5, subgroup analysis was not conducted for the overall analysis because although the effect is estimated to favour HER2+ significantly, in some studies the true effect may in fact favour HER2−.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Thus, four subsequent subgroup analyses—pooling two studies at each treatment regimen the patients were subjected to—were conducted for the overall PR− vs PR+ (adjusted results) analysis (Supplementary Figure 7.4 in Additional file 7).Discussion\nThere are many options for breast cancer treatment.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Fig. 1 shows how the studies were searched and identified in the various databases and registers.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Finally, 101 studies fulfilled the eligibility criteria and were included in the systematic review and meta-analysis (Fig. 1).Overview of included studies\nAltogether, 19,708 Asian breast cancer patients were gathered from the 101 studies, with an average of 195 patients per study (Supplementary Table 4.1 in Additional file 4).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, the role of molecular subtypes was examined in NAC TA-treated (Figure 2 and Supplementary Figure 7.1 in Additional file 7) and TP-treated (Figures 3 and 4 and Supplementary Figure 7.1 in Additional file 7) breast cancer patients.Taxane-anthracycline (TA) chemotherapy\nOur study first compares the effect of HER2E and luminal subtypes on pCR outcomes in TA-treated patients (Fig. 2A–D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Despite the large number of patients with luminal-like subtypes, our findings significantly associate patients with HER2E subtypes with better pCR outcomes (OR: 4.08; 95% CI; 2.78–6.00; p<0.0001; Fig. 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "When HER2E patients were compared with patients with luminal A subtype, patients with HER2E subtypes were also found to be significantly more likely to achieve pCR (OR 5.27; 95% CI 1.16–23.86; p=0.03; Fig. 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Similarly, when HER2E was analysed against luminal B, HER2E was significantly associated with pCR (OR 2.78; 95% CI 1.42–5.44; p=0.003; Fig. 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Nine studies [34, 35, 71, 80, 84, 95, 98, 100, 113] were pooled, yet our findings still showed that HER2E subtype was significantly associated with pCR outcome in NAC TA-treated patients (OR 3.89; 95% CI 2.69-5.64; p<0.0001; Fig. 2D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Similarly, analyses conducted comparing the effect of TNBC and luminal subtypes on pCR outcome in TA-treated patients (Fig. 2E–H) significantly associate TNBC with better pCR outcome compared to luminal-like (OR 4.45; 95% CI 2.79–7.11; p<0.0001; Fig. 2E), luminal A (OR 11.66; 95% CI 3.64-37.38; p<0.0001; Fig. 2F), luminal B (OR 3.89; 95% CI 2.20–6.87; p<0.0001; Fig. 2G), and luminal, combined (OR 4.59; 95% CI 3.35–6.29; p<0.0001; Fig. 2H).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel E",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel E",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel F",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "To further explore the effect of molecular subtypes on the pCR outcome of NAC TA-treated breast cancer patients, the TNBC subtype was compared to the HER2E subtype revealing that neither was associated with pCR (OR 1.17; 95% CI 0.80-1.70; p=0.43; Supplementary Figure 7.1A in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, an analysis between luminal A and luminal B showed that neither was associated with better pCR outcome when treated with NAC TA (OR 2.47; 95% CI 0.79–7.73; p=0.12; Supplementary Figure 7.1B in Additional file 7).Taxane-platinum (TP) chemotherapy\nIn the analysis pooling three studies [45,64,102] comparing HER2E and luminal-like subtypes, 321 patients were identified with HER2E subtype, and 382 patients were luminal-like.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "When treated with NAC TP, neither HER2E nor luminal-like patients were associated with pCR (OR 1.69; 95% CI 0.70–4.11; p=0.25; Fig. 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "However, in the analysis pooling four studies [41, 69, 97, 115] comparing HER2E and luminal A subtypes, HER2E was significantly associated with pCR outcome (OR 12.11; 95% CI 4.41–33.26; p<0.0001; Fig. 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Similarly, when comparing against luminal B and luminal, combined, HER2E was significantly associated with pCR outcome (OR 5.92; 95% CI 2.59–13.54; p<0.0001; Fig. 3C and OR 3.37; 95% CI 1.66–6.84; p=0.0008; Fig. 3D, respectively).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Substantial heterogeneity was reported for two of the pooled analyses: (1) in studies comparing HER2E and luminal-like (Fig. 3A); and (2) in studies comparing HER2E and luminal, combined (Fig. 3D).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Notably, when HER2E and TNBC patients were compared, neither was associated with pCR (OR 1.46; 95% CI 0.63–3.37; p=0.38; Supplementary Figure 7.1C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "We then compared luminal B and luminal A patients and found that luminal B patients were significantly associated with better pCR outcomes (OR 3.26; 95% CI 1.14–9.26; p=0.03; Fig. 3E).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Similar to NAC TA-treated patients, analyses conducted comparing the effect of TNBC and luminal subtypes on pCR outcome in TP-treated patients also significantly associate TNBC with better pCR outcome compared to luminal A (OR 7.14; 95% CI 2.82–18.04; p<0.0001; Fig. 3F), luminal B (OR 2.19; 95% CI 1.09–4.41; p=0.03; Fig. 3G), and luminal, combined (OR 3.79; 95% CI 1.94–7.40; p<0.0001; Fig. 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Our study compared the effect of chemotherapeutic agents on the pCR outcome in TNBC patients (Fig. 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, the role of biomarkers was investigated in NAC anthracycline-based and taxane-based treated (Fig. 4), TA-treated (Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "4, 5 and 6 and Supplementary Figure 7.1 in Additional file 7), and TP-treated (Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "6 and 7) breast cancer patients.Anthracycline-based and taxane-based chemotherapy\nFour studies [53, 88, 102, 124] were pooled for the effect of ER on pCR outcome in anthracycline-treated patients, where ER was not associated with pCR (OR 1.95; 95% CI 0.98–3.89; p=0.06; Fig. 4C).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Subgroup analysis of ER− vs ER+ pooling studies in the Chinese population only showed that ER− patients were significantly associated with pCR (OR 2.52; 95% CI 1.43–4.44; p=0.001; Fig. 4C), supporting our hypothesis that the observed heterogeneity could be due to the difference in the Asian population.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Our findings showed that PR− patients were significantly associated with pCR (OR 2.40; 95% CI 1.52–3.80; p=0.0002; Fig. 4D).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel D",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Meanwhile, an analysis of three pooled studies [88, 102, 109] on the effect of HER2 on pCR outcome in anthracycline-treated breast cancer patients revealed that patients with HER2− biomarker were significantly more likely to achieve pCR (OR 2.31; 95% CI 1.42–3.75; p=0.0008; Fig. 4E).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel E",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Only one biomarker, HR, was evaluated for its effect on pCR outcome in Asian breast cancer patients treated with taxane-based chemotherapy (Fig. 4F).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Both ER− (OR 3.19; 95% CI 2.15–4.75; p<0.0001; Fig. 4G) and PR− (OR 3.11; 95% CI 2.12-4.56; p<0.0001; Fig. 5A) were significantly associated with pCR outcome in TA-treated patients.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel G",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "In an analysis pooling five studies [60, 81, 98, 100, 127], HR was not associated with pCR outcome (OR 2.38; 95% CI 0.87–6.53; p=0.09; Fig. 5B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "An analysis of nine pooled studies [36, 54, 60, 80–82, 100, 113, 127] showed that HER2+ is significantly associated with pCR (OR 1.78; 95% CI 1.05–3.02; p=0.03; Fig. 5C) with substantial heterogeneity observed between the studies.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "It was observed that nm23-H1− (OR 6.74; 95% CI 2.13–21.30; p=0.001; Fig. 5D) and CK5/6– (OR 1.87; 95% CI 1.03–3.39; p=0.04; Fig. 5E) are significantly associated with pCR.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel D",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel E",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Despite that, EGFR is not associated with pCR outcome in TA-treated patients (OR 2.02; 95% CI 0.28–28.00; p=0.38; Supplementary Figure 7.1D in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The proliferation index biomarker, Ki-67, was evaluated through an analysis of 12 pooled studies [12, 36, 54, 60, 80, 84, 90, 95, 98, 100, 111, 127], revealing significant association between pCR outcome and high Ki-67 (OR 2.98; 95% CI 1.79–4.97; p<0.0001; Fig. 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Five studies [41, 43, 97, 114, 115] and two studies [100,102] were pooled to evaluate the association of ER and PR, and HR, respectively. pCR outcome was significantly associated with ER− (OR 4.91; 95% CI 3.20–7.53; p<0.00001; Fig. 6B), PR− (OR 3.82; 95% CI 2.48–5.90; p<0.00001; Fig. 6C), and HR− (OR 2.71; 95% CI 1.43–5.15; p=0.002; Fig. 6D).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel D",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Ki-67 was evaluated by analysing five pooled studies [47, 57, 97, 114, 115], showing that pCR outcome was not significantly associated with either high Ki-67 or low Ki-67 (OR 2.20; 95% CI 0.74–6.59; p=0.16; Fig. 6E).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel E",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "In the analysis of the effect of HER2 in breast cancer patients pooling five studies [41, 43, 97, 114, 115], pCR outcome was not significantly associated with neither HER2+ nor HER2− (OR 2.44; 95% CI 0.84–7.06; p=0.10; Fig. 7A).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel A",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Our study also evaluated the effect of chemotherapeutic agents on the pCR outcome in Asian breast cancer patients with HER2+ biomarker (Fig. 7B).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, only one gene was analysed for its effect on pCR outcome in Asian breast cancer patients treated with NAC TA (Fig. 7).Taxane-anthracycline (TA) chemotherapy\nFrom the analysis of two studies [100, 106], 564 patients were pooled for PIK3CA analysis.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "It was observed that patients harbouring wtPIK3CA were significantly associated with better pCRoutcomes compared to patients with mtPIK3CA gene (OR: 2.44; 95% CI 1.42–4.19; p=0.001; Fig. 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Process\n\nSearch (n=5746)\nExcluded with reasons [refer to Figure 1 for detailed reasons] (n=5610)\nExcluded after reviewing full-text (n=35)\nIncluded studies (n=101)\n\n\n\nResults\n\nWhere statistically appropriate, studies were pooled.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Open in a new tabPooled reported association\nMeta-analyses of pooled reported association of pCR were evaluated according to molecular classification, genetic variations, and biomarkers characterisation of the Asian breast cancer patients.Molecular classification\nAn adjusted pooled analysis of TNBC against non-TNBC patients showed that TNBC patients were significantly associated with better response when treated with neoadjuvant chemotherapy (OR 3.02; 95% CI 1.54–5.95; p=0.001; Supplementary Figure 7.2A in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "In the adjusted analysis of three [51, 100, 106] and two studies [51, 100] for PIK3CA and TP53 genes, respectively, breast cancer patients harbouring mutation in the PIK3CA gene was associated with worse response (OR 0.64; 95% CI 0.42-0.98; p=0.04; Supplementary Figure 7.2B in Additional file 7) while TP53 gene was not associated with pCR outcome (OR 1.34; 95% CI 0.59–3.05; p=0.49; Supplementary Figure 7.2B in Additional file 7).Biomarkers\nAmongst pooled reported associations of pCR for biomarkers, our study evaluated the effect of Tau, nm23-H1, ER, PR, HR, HER2, and Ki-67 biomarkers in NAC-treated Asian BC patients (Supplementary Figures 7.2–7.8 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "In an adjusted analysis of Tau pooling two studies [61, 83], the result suggests that Tau+ was associated with worse response in the neoadjuvant setting (OR 0.22, 95% CI 0.09–0.54, p=0.0008; Supplementary Figure 7.2C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile in adjusted analysis of nm23-H1 pooling two studies [12, 60], nm23-H1 was not associated with pCR outcome in TA-treated patients (OR 1.56, 95% CI 0.55–4.45, p=0.41; Supplementary Figure 7.2C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between pCR in NAC-treated breast cancer patients and ER was evaluated in Supplementary Figure 7.3 (Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile, adjusted analysis of ER+ vs ER− pooling fourteen studies [54, 56, 61, 68, 71, 72, 83, 94, 97, 102, 103, 106, 112, 131] also showed that ER was not associated with pCR outcome (OR 0.59; 95% CI 0.32–1.08; p=0.09; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile, analyses pooling studies based on the characteristics of the patients showed that ER was not associated with pCR in patients achieving a complete pathological response in the breast only (OR 0.93; 95% CI 0.18–4.85; p=0.94; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Notably, ER− patients were significantly associated with pCR in studies pooling anthracycline-treated patients (OR 2.78; 95% CI 1.61–4.78; p=0.0002; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The role of the biomarker PR was assessed in Asian breast cancer patients subjected to neoadjuvant chemotherapy (Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "PR was also not associated with treatment response in the adjusted analysis pooling eight studies [54, 56, 61, 94, 97, 102, 103, 106] (OR 1.01; 95% CI 0.64–1.60; p=0.97; Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between treatment response and hormone receptors (HR) comprising ER and PR was assessed in Asian breast cancer patients (Supplementary Figure 7.5 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, analysis with adjusted OR pooling five studies [51, 60, 62, 64, 70] indicated that HR was not significantly associated with treatment response (OR 1.27; 95% CI 0.47–3.45; p=0.64; Supplementary Figure 7.5 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between pCR outcome and HER2 was estimated in Supplementary Figure 7.6 (Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, in an analysis pooling adjusted OR of 12 studies [56, 60, 61, 70, 77, 83, 94, 97, 102, 103, 106, 131], it was observed that HER2+ breast cancer patients were significantly associated with better treatment response (OR 2.29; 95% CI 1.56–3.35; p<0.0001; Supplementary Figure 7.6 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Notably, HER2 was also not associated with pCR in patients achieving a complete pathological response in the breast only (OR 1.96; 95% CI 0.78–4.89; p=0.15; Supplementary Figure 7.6 in Additional file 7) and in anthracycline-treated patients (OR 1.52; 95% CI 0.97–2.40; p=0.07; Supplementary Figure 7.6 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As for Ki-67, an analysis pooling crude OR of eight studies [46, 51, 61, 64, 94, 97, 115, 123] observed that patients with high Ki-67 were significantly associated with better treatment responses (OR 2.63; 95% CI 1.69–4.07; p<0.0001; Supplementary Figure 7.7 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, an analysis of adjusted OR pooling seven studies [12, 46, 51, 54, 94, 97, 110] showed that patients with high Ki-67 were significantly associated with better treatment response (OR 2.63; 95% CI 1.56–4.41; p=0.0003; Supplementary Figure 7.7 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Three biomarkers—ER, HR, and Ki-67—were evaluated by pooling studies reporting their association using hazards ratio (Supplementary Figure 7.8 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As indicated in Fig. 5, subgroup analysis was not conducted for the overall analysis because although the effect is estimated to favour HER2+ significantly, in some studies the true effect may in fact favour HER2−.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Thus, four subsequent subgroup analyses—pooling two studies at each treatment regimen the patients were subjected to—were conducted for the overall PR− vs PR+ (adjusted results) analysis (Supplementary Figure 7.4 in Additional file 7).Discussion\nThere are many options for breast cancer treatment.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Fig. 1 shows how the studies were searched and identified in the various databases and registers.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Fig. 1 shows how the studies were searched and identified in the various databases and registers.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Fig. 1 shows how the studies were searched and identified in the various databases and registers.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Finally, 101 studies fulfilled the eligibility criteria and were included in the systematic review and meta-analysis (Fig. 1).Overview of included studies\nAltogether, 19,708 Asian breast cancer patients were gathered from the 101 studies, with an average of 195 patients per study (Supplementary Table 4.1 in Additional file 4).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, the role of molecular subtypes was examined in NAC TA-treated (Figure 2 and Supplementary Figure 7.1 in Additional file 7) and TP-treated (Figures 3 and 4 and Supplementary Figure 7.1 in Additional file 7) breast cancer patients.Taxane-anthracycline (TA) chemotherapy\nOur study first compares the effect of HER2E and luminal subtypes on pCR outcomes in TA-treated patients (Fig. 2A–D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Despite the large number of patients with luminal-like subtypes, our findings significantly associate patients with HER2E subtypes with better pCR outcomes (OR: 4.08; 95% CI; 2.78–6.00; p<0.0001; Fig. 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "When HER2E patients were compared with patients with luminal A subtype, patients with HER2E subtypes were also found to be significantly more likely to achieve pCR (OR 5.27; 95% CI 1.16–23.86; p=0.03; Fig. 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Similarly, when HER2E was analysed against luminal B, HER2E was significantly associated with pCR (OR 2.78; 95% CI 1.42–5.44; p=0.003; Fig. 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Nine studies [34, 35, 71, 80, 84, 95, 98, 100, 113] were pooled, yet our findings still showed that HER2E subtype was significantly associated with pCR outcome in NAC TA-treated patients (OR 3.89; 95% CI 2.69-5.64; p<0.0001; Fig. 2D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Similarly, analyses conducted comparing the effect of TNBC and luminal subtypes on pCR outcome in TA-treated patients (Fig. 2E–H) significantly associate TNBC with better pCR outcome compared to luminal-like (OR 4.45; 95% CI 2.79–7.11; p<0.0001; Fig. 2E), luminal A (OR 11.66; 95% CI 3.64-37.38; p<0.0001; Fig. 2F), luminal B (OR 3.89; 95% CI 2.20–6.87; p<0.0001; Fig. 2G), and luminal, combined (OR 4.59; 95% CI 3.35–6.29; p<0.0001; Fig. 2H).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel E",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel E",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel F",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "To further explore the effect of molecular subtypes on the pCR outcome of NAC TA-treated breast cancer patients, the TNBC subtype was compared to the HER2E subtype revealing that neither was associated with pCR (OR 1.17; 95% CI 0.80-1.70; p=0.43; Supplementary Figure 7.1A in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, an analysis between luminal A and luminal B showed that neither was associated with better pCR outcome when treated with NAC TA (OR 2.47; 95% CI 0.79–7.73; p=0.12; Supplementary Figure 7.1B in Additional file 7).Taxane-platinum (TP) chemotherapy\nIn the analysis pooling three studies [45,64,102] comparing HER2E and luminal-like subtypes, 321 patients were identified with HER2E subtype, and 382 patients were luminal-like.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "When treated with NAC TP, neither HER2E nor luminal-like patients were associated with pCR (OR 1.69; 95% CI 0.70–4.11; p=0.25; Fig. 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "However, in the analysis pooling four studies [41, 69, 97, 115] comparing HER2E and luminal A subtypes, HER2E was significantly associated with pCR outcome (OR 12.11; 95% CI 4.41–33.26; p<0.0001; Fig. 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Similarly, when comparing against luminal B and luminal, combined, HER2E was significantly associated with pCR outcome (OR 5.92; 95% CI 2.59–13.54; p<0.0001; Fig. 3C and OR 3.37; 95% CI 1.66–6.84; p=0.0008; Fig. 3D, respectively).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Substantial heterogeneity was reported for two of the pooled analyses: (1) in studies comparing HER2E and luminal-like (Fig. 3A); and (2) in studies comparing HER2E and luminal, combined (Fig. 3D).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Notably, when HER2E and TNBC patients were compared, neither was associated with pCR (OR 1.46; 95% CI 0.63–3.37; p=0.38; Supplementary Figure 7.1C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "We then compared luminal B and luminal A patients and found that luminal B patients were significantly associated with better pCR outcomes (OR 3.26; 95% CI 1.14–9.26; p=0.03; Fig. 3E).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Similar to NAC TA-treated patients, analyses conducted comparing the effect of TNBC and luminal subtypes on pCR outcome in TP-treated patients also significantly associate TNBC with better pCR outcome compared to luminal A (OR 7.14; 95% CI 2.82–18.04; p<0.0001; Fig. 3F), luminal B (OR 2.19; 95% CI 1.09–4.41; p=0.03; Fig. 3G), and luminal, combined (OR 3.79; 95% CI 1.94–7.40; p<0.0001; Fig. 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Our study compared the effect of chemotherapeutic agents on the pCR outcome in TNBC patients (Fig. 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, the role of biomarkers was investigated in NAC anthracycline-based and taxane-based treated (Fig. 4), TA-treated (Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "4, 5 and 6 and Supplementary Figure 7.1 in Additional file 7), and TP-treated (Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "6 and 7) breast cancer patients.Anthracycline-based and taxane-based chemotherapy\nFour studies [53, 88, 102, 124] were pooled for the effect of ER on pCR outcome in anthracycline-treated patients, where ER was not associated with pCR (OR 1.95; 95% CI 0.98–3.89; p=0.06; Fig. 4C).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Subgroup analysis of ER− vs ER+ pooling studies in the Chinese population only showed that ER− patients were significantly associated with pCR (OR 2.52; 95% CI 1.43–4.44; p=0.001; Fig. 4C), supporting our hypothesis that the observed heterogeneity could be due to the difference in the Asian population.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Our findings showed that PR− patients were significantly associated with pCR (OR 2.40; 95% CI 1.52–3.80; p=0.0002; Fig. 4D).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel D",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Meanwhile, an analysis of three pooled studies [88, 102, 109] on the effect of HER2 on pCR outcome in anthracycline-treated breast cancer patients revealed that patients with HER2− biomarker were significantly more likely to achieve pCR (OR 2.31; 95% CI 1.42–3.75; p=0.0008; Fig. 4E).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel E",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Only one biomarker, HR, was evaluated for its effect on pCR outcome in Asian breast cancer patients treated with taxane-based chemotherapy (Fig. 4F).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Both ER− (OR 3.19; 95% CI 2.15–4.75; p<0.0001; Fig. 4G) and PR− (OR 3.11; 95% CI 2.12-4.56; p<0.0001; Fig. 5A) were significantly associated with pCR outcome in TA-treated patients.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel G",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "In an analysis pooling five studies [60, 81, 98, 100, 127], HR was not associated with pCR outcome (OR 2.38; 95% CI 0.87–6.53; p=0.09; Fig. 5B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "An analysis of nine pooled studies [36, 54, 60, 80–82, 100, 113, 127] showed that HER2+ is significantly associated with pCR (OR 1.78; 95% CI 1.05–3.02; p=0.03; Fig. 5C) with substantial heterogeneity observed between the studies.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "It was observed that nm23-H1− (OR 6.74; 95% CI 2.13–21.30; p=0.001; Fig. 5D) and CK5/6– (OR 1.87; 95% CI 1.03–3.39; p=0.04; Fig. 5E) are significantly associated with pCR.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel D",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel E",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Despite that, EGFR is not associated with pCR outcome in TA-treated patients (OR 2.02; 95% CI 0.28–28.00; p=0.38; Supplementary Figure 7.1D in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The proliferation index biomarker, Ki-67, was evaluated through an analysis of 12 pooled studies [12, 36, 54, 60, 80, 84, 90, 95, 98, 100, 111, 127], revealing significant association between pCR outcome and high Ki-67 (OR 2.98; 95% CI 1.79–4.97; p<0.0001; Fig. 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Five studies [41, 43, 97, 114, 115] and two studies [100,102] were pooled to evaluate the association of ER and PR, and HR, respectively. pCR outcome was significantly associated with ER− (OR 4.91; 95% CI 3.20–7.53; p<0.00001; Fig. 6B), PR− (OR 3.82; 95% CI 2.48–5.90; p<0.00001; Fig. 6C), and HR− (OR 2.71; 95% CI 1.43–5.15; p=0.002; Fig. 6D).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel D",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Ki-67 was evaluated by analysing five pooled studies [47, 57, 97, 114, 115], showing that pCR outcome was not significantly associated with either high Ki-67 or low Ki-67 (OR 2.20; 95% CI 0.74–6.59; p=0.16; Fig. 6E).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel E",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "In the analysis of the effect of HER2 in breast cancer patients pooling five studies [41, 43, 97, 114, 115], pCR outcome was not significantly associated with neither HER2+ nor HER2− (OR 2.44; 95% CI 0.84–7.06; p=0.10; Fig. 7A).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel A",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Our study also evaluated the effect of chemotherapeutic agents on the pCR outcome in Asian breast cancer patients with HER2+ biomarker (Fig. 7B).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, only one gene was analysed for its effect on pCR outcome in Asian breast cancer patients treated with NAC TA (Fig. 7).Taxane-anthracycline (TA) chemotherapy\nFrom the analysis of two studies [100, 106], 564 patients were pooled for PIK3CA analysis.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "It was observed that patients harbouring wtPIK3CA were significantly associated with better pCRoutcomes compared to patients with mtPIK3CA gene (OR: 2.44; 95% CI 1.42–4.19; p=0.001; Fig. 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Process\n\nSearch (n=5746)\nExcluded with reasons [refer to Figure 1 for detailed reasons] (n=5610)\nExcluded after reviewing full-text (n=35)\nIncluded studies (n=101)\n\n\n\nResults\n\nWhere statistically appropriate, studies were pooled.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Open in a new tabPooled reported association\nMeta-analyses of pooled reported association of pCR were evaluated according to molecular classification, genetic variations, and biomarkers characterisation of the Asian breast cancer patients.Molecular classification\nAn adjusted pooled analysis of TNBC against non-TNBC patients showed that TNBC patients were significantly associated with better response when treated with neoadjuvant chemotherapy (OR 3.02; 95% CI 1.54–5.95; p=0.001; Supplementary Figure 7.2A in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "In the adjusted analysis of three [51, 100, 106] and two studies [51, 100] for PIK3CA and TP53 genes, respectively, breast cancer patients harbouring mutation in the PIK3CA gene was associated with worse response (OR 0.64; 95% CI 0.42-0.98; p=0.04; Supplementary Figure 7.2B in Additional file 7) while TP53 gene was not associated with pCR outcome (OR 1.34; 95% CI 0.59–3.05; p=0.49; Supplementary Figure 7.2B in Additional file 7).Biomarkers\nAmongst pooled reported associations of pCR for biomarkers, our study evaluated the effect of Tau, nm23-H1, ER, PR, HR, HER2, and Ki-67 biomarkers in NAC-treated Asian BC patients (Supplementary Figures 7.2–7.8 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "In an adjusted analysis of Tau pooling two studies [61, 83], the result suggests that Tau+ was associated with worse response in the neoadjuvant setting (OR 0.22, 95% CI 0.09–0.54, p=0.0008; Supplementary Figure 7.2C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile in adjusted analysis of nm23-H1 pooling two studies [12, 60], nm23-H1 was not associated with pCR outcome in TA-treated patients (OR 1.56, 95% CI 0.55–4.45, p=0.41; Supplementary Figure 7.2C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between pCR in NAC-treated breast cancer patients and ER was evaluated in Supplementary Figure 7.3 (Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile, adjusted analysis of ER+ vs ER− pooling fourteen studies [54, 56, 61, 68, 71, 72, 83, 94, 97, 102, 103, 106, 112, 131] also showed that ER was not associated with pCR outcome (OR 0.59; 95% CI 0.32–1.08; p=0.09; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile, analyses pooling studies based on the characteristics of the patients showed that ER was not associated with pCR in patients achieving a complete pathological response in the breast only (OR 0.93; 95% CI 0.18–4.85; p=0.94; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Notably, ER− patients were significantly associated with pCR in studies pooling anthracycline-treated patients (OR 2.78; 95% CI 1.61–4.78; p=0.0002; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The role of the biomarker PR was assessed in Asian breast cancer patients subjected to neoadjuvant chemotherapy (Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "PR was also not associated with treatment response in the adjusted analysis pooling eight studies [54, 56, 61, 94, 97, 102, 103, 106] (OR 1.01; 95% CI 0.64–1.60; p=0.97; Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between treatment response and hormone receptors (HR) comprising ER and PR was assessed in Asian breast cancer patients (Supplementary Figure 7.5 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, analysis with adjusted OR pooling five studies [51, 60, 62, 64, 70] indicated that HR was not significantly associated with treatment response (OR 1.27; 95% CI 0.47–3.45; p=0.64; Supplementary Figure 7.5 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between pCR outcome and HER2 was estimated in Supplementary Figure 7.6 (Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, in an analysis pooling adjusted OR of 12 studies [56, 60, 61, 70, 77, 83, 94, 97, 102, 103, 106, 131], it was observed that HER2+ breast cancer patients were significantly associated with better treatment response (OR 2.29; 95% CI 1.56–3.35; p<0.0001; Supplementary Figure 7.6 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Notably, HER2 was also not associated with pCR in patients achieving a complete pathological response in the breast only (OR 1.96; 95% CI 0.78–4.89; p=0.15; Supplementary Figure 7.6 in Additional file 7) and in anthracycline-treated patients (OR 1.52; 95% CI 0.97–2.40; p=0.07; Supplementary Figure 7.6 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As for Ki-67, an analysis pooling crude OR of eight studies [46, 51, 61, 64, 94, 97, 115, 123] observed that patients with high Ki-67 were significantly associated with better treatment responses (OR 2.63; 95% CI 1.69–4.07; p<0.0001; Supplementary Figure 7.7 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, an analysis of adjusted OR pooling seven studies [12, 46, 51, 54, 94, 97, 110] showed that patients with high Ki-67 were significantly associated with better treatment response (OR 2.63; 95% CI 1.56–4.41; p=0.0003; Supplementary Figure 7.7 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Three biomarkers—ER, HR, and Ki-67—were evaluated by pooling studies reporting their association using hazards ratio (Supplementary Figure 7.8 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As indicated in Fig. 5, subgroup analysis was not conducted for the overall analysis because although the effect is estimated to favour HER2+ significantly, in some studies the true effect may in fact favour HER2−.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Thus, four subsequent subgroup analyses—pooling two studies at each treatment regimen the patients were subjected to—were conducted for the overall PR− vs PR+ (adjusted results) analysis (Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Finally, 101 studies fulfilled the eligibility criteria and were included in the systematic review and meta-analysis (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Finally, 101 studies fulfilled the eligibility criteria and were included in the systematic review and meta-analysis (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, the role of molecular subtypes was examined in NAC TA-treated (Figure 2 and Supplementary Figure 7.1 in Additional file 7) and TP-treated (Figures 3 and 4 and Supplementary Figure 7.1 in Additional file 7) breast cancer patients.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, the role of molecular subtypes was examined in NAC TA-treated (Figure 2 and Supplementary Figure 7.1 in Additional file 7) and TP-treated (Figures 3 and 4 and Supplementary Figure 7.1 in Additional file 7) breast cancer patients.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Taxane-anthracycline (TA) chemotherapy\nOur study first compares the effect of HER2E and luminal subtypes on pCR outcomes in TA-treated patients (Fig. 2A–D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Despite the large number of patients with luminal-like subtypes, our findings significantly associate patients with HER2E subtypes with better pCR outcomes (OR: 4.08; 95% CI; 2.78–6.00; p<0.0001; Fig. 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "When HER2E patients were compared with patients with luminal A subtype, patients with HER2E subtypes were also found to be significantly more likely to achieve pCR (OR 5.27; 95% CI 1.16–23.86; p=0.03; Fig. 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Similarly, when HER2E was analysed against luminal B, HER2E was significantly associated with pCR (OR 2.78; 95% CI 1.42–5.44; p=0.003; Fig. 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Nine studies [34, 35, 71, 80, 84, 95, 98, 100, 113] were pooled, yet our findings still showed that HER2E subtype was significantly associated with pCR outcome in NAC TA-treated patients (OR 3.89; 95% CI 2.69-5.64; p<0.0001; Fig. 2D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Similarly, analyses conducted comparing the effect of TNBC and luminal subtypes on pCR outcome in TA-treated patients (Fig. 2E–H) significantly associate TNBC with better pCR outcome compared to luminal-like (OR 4.45; 95% CI 2.79–7.11; p<0.0001; Fig. 2E), luminal A (OR 11.66; 95% CI 3.64-37.38; p<0.0001; Fig. 2F), luminal B (OR 3.89; 95% CI 2.20–6.87; p<0.0001; Fig. 2G), and luminal, combined (OR 4.59; 95% CI 3.35–6.29; p<0.0001; Fig. 2H).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel E",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel E",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel F",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "To further explore the effect of molecular subtypes on the pCR outcome of NAC TA-treated breast cancer patients, the TNBC subtype was compared to the HER2E subtype revealing that neither was associated with pCR (OR 1.17; 95% CI 0.80-1.70; p=0.43; Supplementary Figure 7.1A in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, an analysis between luminal A and luminal B showed that neither was associated with better pCR outcome when treated with NAC TA (OR 2.47; 95% CI 0.79–7.73; p=0.12; Supplementary Figure 7.1B in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Our study first compares the effect of HER2E and luminal subtypes on pCR outcomes in TA-treated patients (Fig. 2A–D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Despite the large number of patients with luminal-like subtypes, our findings significantly associate patients with HER2E subtypes with better pCR outcomes (OR: 4.08; 95% CI; 2.78–6.00; p<0.0001; Fig. 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "When HER2E patients were compared with patients with luminal A subtype, patients with HER2E subtypes were also found to be significantly more likely to achieve pCR (OR 5.27; 95% CI 1.16–23.86; p=0.03; Fig. 2B).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Similarly, when HER2E was analysed against luminal B, HER2E was significantly associated with pCR (OR 2.78; 95% CI 1.42–5.44; p=0.003; Fig. 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Nine studies [34, 35, 71, 80, 84, 95, 98, 100, 113] were pooled, yet our findings still showed that HER2E subtype was significantly associated with pCR outcome in NAC TA-treated patients (OR 3.89; 95% CI 2.69-5.64; p<0.0001; Fig. 2D).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Similarly, analyses conducted comparing the effect of TNBC and luminal subtypes on pCR outcome in TA-treated patients (Fig. 2E–H) significantly associate TNBC with better pCR outcome compared to luminal-like (OR 4.45; 95% CI 2.79–7.11; p<0.0001; Fig. 2E), luminal A (OR 11.66; 95% CI 3.64-37.38; p<0.0001; Fig. 2F), luminal B (OR 3.89; 95% CI 2.20–6.87; p<0.0001; Fig. 2G), and luminal, combined (OR 4.59; 95% CI 3.35–6.29; p<0.0001; Fig. 2H).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel E",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel E",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel F",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel G",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel H",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "To further explore the effect of molecular subtypes on the pCR outcome of NAC TA-treated breast cancer patients, the TNBC subtype was compared to the HER2E subtype revealing that neither was associated with pCR (OR 1.17; 95% CI 0.80-1.70; p=0.43; Supplementary Figure 7.1A in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, an analysis between luminal A and luminal B showed that neither was associated with better pCR outcome when treated with NAC TA (OR 2.47; 95% CI 0.79–7.73; p=0.12; Supplementary Figure 7.1B in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "When treated with NAC TP, neither HER2E nor luminal-like patients were associated with pCR (OR 1.69; 95% CI 0.70–4.11; p=0.25; Fig. 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "However, in the analysis pooling four studies [41, 69, 97, 115] comparing HER2E and luminal A subtypes, HER2E was significantly associated with pCR outcome (OR 12.11; 95% CI 4.41–33.26; p<0.0001; Fig. 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Similarly, when comparing against luminal B and luminal, combined, HER2E was significantly associated with pCR outcome (OR 5.92; 95% CI 2.59–13.54; p<0.0001; Fig. 3C and OR 3.37; 95% CI 1.66–6.84; p=0.0008; Fig. 3D, respectively).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Substantial heterogeneity was reported for two of the pooled analyses: (1) in studies comparing HER2E and luminal-like (Fig. 3A); and (2) in studies comparing HER2E and luminal, combined (Fig. 3D).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Notably, when HER2E and TNBC patients were compared, neither was associated with pCR (OR 1.46; 95% CI 0.63–3.37; p=0.38; Supplementary Figure 7.1C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "We then compared luminal B and luminal A patients and found that luminal B patients were significantly associated with better pCR outcomes (OR 3.26; 95% CI 1.14–9.26; p=0.03; Fig. 3E).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Similar to NAC TA-treated patients, analyses conducted comparing the effect of TNBC and luminal subtypes on pCR outcome in TP-treated patients also significantly associate TNBC with better pCR outcome compared to luminal A (OR 7.14; 95% CI 2.82–18.04; p<0.0001; Fig. 3F), luminal B (OR 2.19; 95% CI 1.09–4.41; p=0.03; Fig. 3G), and luminal, combined (OR 3.79; 95% CI 1.94–7.40; p<0.0001; Fig. 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Our study compared the effect of chemotherapeutic agents on the pCR outcome in TNBC patients (Fig. 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "When treated with NAC TP, neither HER2E nor luminal-like patients were associated with pCR (OR 1.69; 95% CI 0.70–4.11; p=0.25; Fig. 3A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "However, in the analysis pooling four studies [41, 69, 97, 115] comparing HER2E and luminal A subtypes, HER2E was significantly associated with pCR outcome (OR 12.11; 95% CI 4.41–33.26; p<0.0001; Fig. 3B).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel B",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Similarly, when comparing against luminal B and luminal, combined, HER2E was significantly associated with pCR outcome (OR 5.92; 95% CI 2.59–13.54; p<0.0001; Fig. 3C and OR 3.37; 95% CI 1.66–6.84; p=0.0008; Fig. 3D, respectively).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel C",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Substantial heterogeneity was reported for two of the pooled analyses: (1) in studies comparing HER2E and luminal-like (Fig. 3A); and (2) in studies comparing HER2E and luminal, combined (Fig. 3D).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel A",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel D",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Notably, when HER2E and TNBC patients were compared, neither was associated with pCR (OR 1.46; 95% CI 0.63–3.37; p=0.38; Supplementary Figure 7.1C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "We then compared luminal B and luminal A patients and found that luminal B patients were significantly associated with better pCR outcomes (OR 3.26; 95% CI 1.14–9.26; p=0.03; Fig. 3E).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel E",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Similar to NAC TA-treated patients, analyses conducted comparing the effect of TNBC and luminal subtypes on pCR outcome in TP-treated patients also significantly associate TNBC with better pCR outcome compared to luminal A (OR 7.14; 95% CI 2.82–18.04; p<0.0001; Fig. 3F), luminal B (OR 2.19; 95% CI 1.09–4.41; p=0.03; Fig. 3G), and luminal, combined (OR 3.79; 95% CI 1.94–7.40; p<0.0001; Fig. 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "Panel F",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "Panel G",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Our study compared the effect of chemotherapeutic agents on the pCR outcome in TNBC patients (Fig. 4B).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, the role of biomarkers was investigated in NAC anthracycline-based and taxane-based treated (Fig. 4), TA-treated (Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "4, 5 and 6 and Supplementary Figure 7.1 in Additional file 7), and TP-treated (Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, the role of biomarkers was investigated in NAC anthracycline-based and taxane-based treated (Fig. 4), TA-treated (Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "4, 5 and 6 and Supplementary Figure 7.1 in Additional file 7), and TP-treated (Figs.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Anthracycline-based and taxane-based chemotherapy\nFour studies [53, 88, 102, 124] were pooled for the effect of ER on pCR outcome in anthracycline-treated patients, where ER was not associated with pCR (OR 1.95; 95% CI 0.98–3.89; p=0.06; Fig. 4C).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Subgroup analysis of ER− vs ER+ pooling studies in the Chinese population only showed that ER− patients were significantly associated with pCR (OR 2.52; 95% CI 1.43–4.44; p=0.001; Fig. 4C), supporting our hypothesis that the observed heterogeneity could be due to the difference in the Asian population.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Our findings showed that PR− patients were significantly associated with pCR (OR 2.40; 95% CI 1.52–3.80; p=0.0002; Fig. 4D).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel D",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Meanwhile, an analysis of three pooled studies [88, 102, 109] on the effect of HER2 on pCR outcome in anthracycline-treated breast cancer patients revealed that patients with HER2− biomarker were significantly more likely to achieve pCR (OR 2.31; 95% CI 1.42–3.75; p=0.0008; Fig. 4E).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel E",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Only one biomarker, HR, was evaluated for its effect on pCR outcome in Asian breast cancer patients treated with taxane-based chemotherapy (Fig. 4F).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Four studies [53, 88, 102, 124] were pooled for the effect of ER on pCR outcome in anthracycline-treated patients, where ER was not associated with pCR (OR 1.95; 95% CI 0.98–3.89; p=0.06; Fig. 4C).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Subgroup analysis of ER− vs ER+ pooling studies in the Chinese population only showed that ER− patients were significantly associated with pCR (OR 2.52; 95% CI 1.43–4.44; p=0.001; Fig. 4C), supporting our hypothesis that the observed heterogeneity could be due to the difference in the Asian population.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel C",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Our findings showed that PR− patients were significantly associated with pCR (OR 2.40; 95% CI 1.52–3.80; p=0.0002; Fig. 4D).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel D",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Meanwhile, an analysis of three pooled studies [88, 102, 109] on the effect of HER2 on pCR outcome in anthracycline-treated breast cancer patients revealed that patients with HER2− biomarker were significantly more likely to achieve pCR (OR 2.31; 95% CI 1.42–3.75; p=0.0008; Fig. 4E).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel E",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Only one biomarker, HR, was evaluated for its effect on pCR outcome in Asian breast cancer patients treated with taxane-based chemotherapy (Fig. 4F).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel F",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Both ER− (OR 3.19; 95% CI 2.15–4.75; p<0.0001; Fig. 4G) and PR− (OR 3.11; 95% CI 2.12-4.56; p<0.0001; Fig. 5A) were significantly associated with pCR outcome in TA-treated patients.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel G",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "In an analysis pooling five studies [60, 81, 98, 100, 127], HR was not associated with pCR outcome (OR 2.38; 95% CI 0.87–6.53; p=0.09; Fig. 5B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "An analysis of nine pooled studies [36, 54, 60, 80–82, 100, 113, 127] showed that HER2+ is significantly associated with pCR (OR 1.78; 95% CI 1.05–3.02; p=0.03; Fig. 5C) with substantial heterogeneity observed between the studies.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "It was observed that nm23-H1− (OR 6.74; 95% CI 2.13–21.30; p=0.001; Fig. 5D) and CK5/6– (OR 1.87; 95% CI 1.03–3.39; p=0.04; Fig. 5E) are significantly associated with pCR.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel D",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel E",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Despite that, EGFR is not associated with pCR outcome in TA-treated patients (OR 2.02; 95% CI 0.28–28.00; p=0.38; Supplementary Figure 7.1D in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The proliferation index biomarker, Ki-67, was evaluated through an analysis of 12 pooled studies [12, 36, 54, 60, 80, 84, 90, 95, 98, 100, 111, 127], revealing significant association between pCR outcome and high Ki-67 (OR 2.98; 95% CI 1.79–4.97; p<0.0001; Fig. 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Both ER− (OR 3.19; 95% CI 2.15–4.75; p<0.0001; Fig. 4G) and PR− (OR 3.11; 95% CI 2.12-4.56; p<0.0001; Fig. 5A) were significantly associated with pCR outcome in TA-treated patients.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel G",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "In an analysis pooling five studies [60, 81, 98, 100, 127], HR was not associated with pCR outcome (OR 2.38; 95% CI 0.87–6.53; p=0.09; Fig. 5B).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel B",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "An analysis of nine pooled studies [36, 54, 60, 80–82, 100, 113, 127] showed that HER2+ is significantly associated with pCR (OR 1.78; 95% CI 1.05–3.02; p=0.03; Fig. 5C) with substantial heterogeneity observed between the studies.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "It was observed that nm23-H1− (OR 6.74; 95% CI 2.13–21.30; p=0.001; Fig. 5D) and CK5/6– (OR 1.87; 95% CI 1.03–3.39; p=0.04; Fig. 5E) are significantly associated with pCR.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel D",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel E",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Despite that, EGFR is not associated with pCR outcome in TA-treated patients (OR 2.02; 95% CI 0.28–28.00; p=0.38; Supplementary Figure 7.1D in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The proliferation index biomarker, Ki-67, was evaluated through an analysis of 12 pooled studies [12, 36, 54, 60, 80, 84, 90, 95, 98, 100, 111, 127], revealing significant association between pCR outcome and high Ki-67 (OR 2.98; 95% CI 1.79–4.97; p<0.0001; Fig. 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Five studies [41, 43, 97, 114, 115] and two studies [100,102] were pooled to evaluate the association of ER and PR, and HR, respectively. pCR outcome was significantly associated with ER− (OR 4.91; 95% CI 3.20–7.53; p<0.00001; Fig. 6B), PR− (OR 3.82; 95% CI 2.48–5.90; p<0.00001; Fig. 6C), and HR− (OR 2.71; 95% CI 1.43–5.15; p=0.002; Fig. 6D).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel D",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Ki-67 was evaluated by analysing five pooled studies [47, 57, 97, 114, 115], showing that pCR outcome was not significantly associated with either high Ki-67 or low Ki-67 (OR 2.20; 95% CI 0.74–6.59; p=0.16; Fig. 6E).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel E",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "In the analysis of the effect of HER2 in breast cancer patients pooling five studies [41, 43, 97, 114, 115], pCR outcome was not significantly associated with neither HER2+ nor HER2− (OR 2.44; 95% CI 0.84–7.06; p=0.10; Fig. 7A).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel A",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Our study also evaluated the effect of chemotherapeutic agents on the pCR outcome in Asian breast cancer patients with HER2+ biomarker (Fig. 7B).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Five studies [41, 43, 97, 114, 115] and two studies [100,102] were pooled to evaluate the association of ER and PR, and HR, respectively. pCR outcome was significantly associated with ER− (OR 4.91; 95% CI 3.20–7.53; p<0.00001; Fig. 6B), PR− (OR 3.82; 95% CI 2.48–5.90; p<0.00001; Fig. 6C), and HR− (OR 2.71; 95% CI 1.43–5.15; p=0.002; Fig. 6D).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel D",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Ki-67 was evaluated by analysing five pooled studies [47, 57, 97, 114, 115], showing that pCR outcome was not significantly associated with either high Ki-67 or low Ki-67 (OR 2.20; 95% CI 0.74–6.59; p=0.16; Fig. 6E).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel E",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "In the analysis of the effect of HER2 in breast cancer patients pooling five studies [41, 43, 97, 114, 115], pCR outcome was not significantly associated with neither HER2+ nor HER2− (OR 2.44; 95% CI 0.84–7.06; p=0.10; Fig. 7A).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel A",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Our study also evaluated the effect of chemotherapeutic agents on the pCR outcome in Asian breast cancer patients with HER2+ biomarker (Fig. 7B).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel B",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, only one gene was analysed for its effect on pCR outcome in Asian breast cancer patients treated with NAC TA (Fig. 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Under meta-analysis, only one gene was analysed for its effect on pCR outcome in Asian breast cancer patients treated with NAC TA (Fig. 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "It was observed that patients harbouring wtPIK3CA were significantly associated with better pCRoutcomes compared to patients with mtPIK3CA gene (OR: 2.44; 95% CI 1.42–4.19; p=0.001; Fig. 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Process\n\nSearch (n=5746)\nExcluded with reasons [refer to Figure 1 for detailed reasons] (n=5610)\nExcluded after reviewing full-text (n=35)\nIncluded studies (n=101)\n\n\n\nResults\n\nWhere statistically appropriate, studies were pooled.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "It was observed that patients harbouring wtPIK3CA were significantly associated with better pCRoutcomes compared to patients with mtPIK3CA gene (OR: 2.44; 95% CI 1.42–4.19; p=0.001; Fig. 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Process\n\nSearch (n=5746)\nExcluded with reasons [refer to Figure 1 for detailed reasons] (n=5610)\nExcluded after reviewing full-text (n=35)\nIncluded studies (n=101)\n\n\n\nResults\n\nWhere statistically appropriate, studies were pooled.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Process\n\nSearch (n=5746)\nExcluded with reasons [refer to Figure 1 for detailed reasons] (n=5610)\nExcluded after reviewing full-text (n=35)\nIncluded studies (n=101)\n\n\n\nResults\n\nWhere statistically appropriate, studies were pooled.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Excluded with reasons [refer to Figure 1 for detailed reasons] (n=5610).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Molecular classification\nAn adjusted pooled analysis of TNBC against non-TNBC patients showed that TNBC patients were significantly associated with better response when treated with neoadjuvant chemotherapy (OR 3.02; 95% CI 1.54–5.95; p=0.001; Supplementary Figure 7.2A in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "An adjusted pooled analysis of TNBC against non-TNBC patients showed that TNBC patients were significantly associated with better response when treated with neoadjuvant chemotherapy (OR 3.02; 95% CI 1.54–5.95; p=0.001; Supplementary Figure 7.2A in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "In the adjusted analysis of three [51, 100, 106] and two studies [51, 100] for PIK3CA and TP53 genes, respectively, breast cancer patients harbouring mutation in the PIK3CA gene was associated with worse response (OR 0.64; 95% CI 0.42-0.98; p=0.04; Supplementary Figure 7.2B in Additional file 7) while TP53 gene was not associated with pCR outcome (OR 1.34; 95% CI 0.59–3.05; p=0.49; Supplementary Figure 7.2B in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "In the adjusted analysis of three [51, 100, 106] and two studies [51, 100] for PIK3CA and TP53 genes, respectively, breast cancer patients harbouring mutation in the PIK3CA gene was associated with worse response (OR 0.64; 95% CI 0.42-0.98; p=0.04; Supplementary Figure 7.2B in Additional file 7) while TP53 gene was not associated with pCR outcome (OR 1.34; 95% CI 0.59–3.05; p=0.49; Supplementary Figure 7.2B in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "In an adjusted analysis of Tau pooling two studies [61, 83], the result suggests that Tau+ was associated with worse response in the neoadjuvant setting (OR 0.22, 95% CI 0.09–0.54, p=0.0008; Supplementary Figure 7.2C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile in adjusted analysis of nm23-H1 pooling two studies [12, 60], nm23-H1 was not associated with pCR outcome in TA-treated patients (OR 1.56, 95% CI 0.55–4.45, p=0.41; Supplementary Figure 7.2C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between pCR in NAC-treated breast cancer patients and ER was evaluated in Supplementary Figure 7.3 (Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile, adjusted analysis of ER+ vs ER− pooling fourteen studies [54, 56, 61, 68, 71, 72, 83, 94, 97, 102, 103, 106, 112, 131] also showed that ER was not associated with pCR outcome (OR 0.59; 95% CI 0.32–1.08; p=0.09; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile, analyses pooling studies based on the characteristics of the patients showed that ER was not associated with pCR in patients achieving a complete pathological response in the breast only (OR 0.93; 95% CI 0.18–4.85; p=0.94; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Notably, ER− patients were significantly associated with pCR in studies pooling anthracycline-treated patients (OR 2.78; 95% CI 1.61–4.78; p=0.0002; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The role of the biomarker PR was assessed in Asian breast cancer patients subjected to neoadjuvant chemotherapy (Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "PR was also not associated with treatment response in the adjusted analysis pooling eight studies [54, 56, 61, 94, 97, 102, 103, 106] (OR 1.01; 95% CI 0.64–1.60; p=0.97; Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between treatment response and hormone receptors (HR) comprising ER and PR was assessed in Asian breast cancer patients (Supplementary Figure 7.5 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, analysis with adjusted OR pooling five studies [51, 60, 62, 64, 70] indicated that HR was not significantly associated with treatment response (OR 1.27; 95% CI 0.47–3.45; p=0.64; Supplementary Figure 7.5 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between pCR outcome and HER2 was estimated in Supplementary Figure 7.6 (Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, in an analysis pooling adjusted OR of 12 studies [56, 60, 61, 70, 77, 83, 94, 97, 102, 103, 106, 131], it was observed that HER2+ breast cancer patients were significantly associated with better treatment response (OR 2.29; 95% CI 1.56–3.35; p<0.0001; Supplementary Figure 7.6 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Notably, HER2 was also not associated with pCR in patients achieving a complete pathological response in the breast only (OR 1.96; 95% CI 0.78–4.89; p=0.15; Supplementary Figure 7.6 in Additional file 7) and in anthracycline-treated patients (OR 1.52; 95% CI 0.97–2.40; p=0.07; Supplementary Figure 7.6 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As for Ki-67, an analysis pooling crude OR of eight studies [46, 51, 61, 64, 94, 97, 115, 123] observed that patients with high Ki-67 were significantly associated with better treatment responses (OR 2.63; 95% CI 1.69–4.07; p<0.0001; Supplementary Figure 7.7 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, an analysis of adjusted OR pooling seven studies [12, 46, 51, 54, 94, 97, 110] showed that patients with high Ki-67 were significantly associated with better treatment response (OR 2.63; 95% CI 1.56–4.41; p=0.0003; Supplementary Figure 7.7 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Three biomarkers—ER, HR, and Ki-67—were evaluated by pooling studies reporting their association using hazards ratio (Supplementary Figure 7.8 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "In an adjusted analysis of Tau pooling two studies [61, 83], the result suggests that Tau+ was associated with worse response in the neoadjuvant setting (OR 0.22, 95% CI 0.09–0.54, p=0.0008; Supplementary Figure 7.2C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile in adjusted analysis of nm23-H1 pooling two studies [12, 60], nm23-H1 was not associated with pCR outcome in TA-treated patients (OR 1.56, 95% CI 0.55–4.45, p=0.41; Supplementary Figure 7.2C in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between pCR in NAC-treated breast cancer patients and ER was evaluated in Supplementary Figure 7.3 (Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile, adjusted analysis of ER+ vs ER− pooling fourteen studies [54, 56, 61, 68, 71, 72, 83, 94, 97, 102, 103, 106, 112, 131] also showed that ER was not associated with pCR outcome (OR 0.59; 95% CI 0.32–1.08; p=0.09; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Meanwhile, analyses pooling studies based on the characteristics of the patients showed that ER was not associated with pCR in patients achieving a complete pathological response in the breast only (OR 0.93; 95% CI 0.18–4.85; p=0.94; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Notably, ER− patients were significantly associated with pCR in studies pooling anthracycline-treated patients (OR 2.78; 95% CI 1.61–4.78; p=0.0002; Supplementary Figure 7.3 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The role of the biomarker PR was assessed in Asian breast cancer patients subjected to neoadjuvant chemotherapy (Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "PR was also not associated with treatment response in the adjusted analysis pooling eight studies [54, 56, 61, 94, 97, 102, 103, 106] (OR 1.01; 95% CI 0.64–1.60; p=0.97; Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between treatment response and hormone receptors (HR) comprising ER and PR was assessed in Asian breast cancer patients (Supplementary Figure 7.5 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, analysis with adjusted OR pooling five studies [51, 60, 62, 64, 70] indicated that HR was not significantly associated with treatment response (OR 1.27; 95% CI 0.47–3.45; p=0.64; Supplementary Figure 7.5 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The association between pCR outcome and HER2 was estimated in Supplementary Figure 7.6 (Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, in an analysis pooling adjusted OR of 12 studies [56, 60, 61, 70, 77, 83, 94, 97, 102, 103, 106, 131], it was observed that HER2+ breast cancer patients were significantly associated with better treatment response (OR 2.29; 95% CI 1.56–3.35; p<0.0001; Supplementary Figure 7.6 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Notably, HER2 was also not associated with pCR in patients achieving a complete pathological response in the breast only (OR 1.96; 95% CI 0.78–4.89; p=0.15; Supplementary Figure 7.6 in Additional file 7) and in anthracycline-treated patients (OR 1.52; 95% CI 0.97–2.40; p=0.07; Supplementary Figure 7.6 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As for Ki-67, an analysis pooling crude OR of eight studies [46, 51, 61, 64, 94, 97, 115, 123] observed that patients with high Ki-67 were significantly associated with better treatment responses (OR 2.63; 95% CI 1.69–4.07; p<0.0001; Supplementary Figure 7.7 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, an analysis of adjusted OR pooling seven studies [12, 46, 51, 54, 94, 97, 110] showed that patients with high Ki-67 were significantly associated with better treatment response (OR 2.63; 95% CI 1.56–4.41; p=0.0003; Supplementary Figure 7.7 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Three biomarkers—ER, HR, and Ki-67—were evaluated by pooling studies reporting their association using hazards ratio (Supplementary Figure 7.8 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As indicated in Fig. 5, subgroup analysis was not conducted for the overall analysis because although the effect is estimated to favour HER2+ significantly, in some studies the true effect may in fact favour HER2−.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Thus, four subsequent subgroup analyses—pooling two studies at each treatment regimen the patients were subjected to—were conducted for the overall PR− vs PR+ (adjusted results) analysis (Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As indicated in Fig. 5, subgroup analysis was not conducted for the overall analysis because although the effect is estimated to favour HER2+ significantly, in some studies the true effect may in fact favour HER2−.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Thus, four subsequent subgroup analyses—pooling two studies at each treatment regimen the patients were subjected to—were conducted for the overall PR− vs PR+ (adjusted results) analysis (Supplementary Figure 7.4 in Additional file 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.1.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 6.2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.1.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.2.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.3.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.4.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.5.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.6.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 7.8.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.1.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.2.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.3.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.4.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.5.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.6.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.7.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.8.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.9.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.10.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.11.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.12.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Supplementary Figure 8.13.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 7,
    "claims_count": 1263,
    "images_downloaded": 7,
    "tables_filtered": 45
  }
}